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Next-generation (high throughput) DNA sequencing of immunoglobulin variable 
region and T-cell receptor gene repertoires is providing critical information for 
understanding adaptive immune responses and for diagnostic and therapeutic 
applications
1–4
.  However, existing immune repertoire sequencing technologies yield data 
on only one of the two chains of immune receptors and thus cannot provide information 
on the identity of immune receptor pairs encoded by individual B or T lymphocytes
5–7
.  
This work directly addressed these limitations by developing two new technologies for 
sequencing the complementary DNA (cDNA) of multiple mRNA transcripts from 
isolated single cells with very high throughput.  In these methods, cells are sequestered 
into individual compartments and lysed in situ to capture single-cell mRNA onto 
magnetic beads, then the magnetic beads are used as template for RT-PCR reactions 
inside emulsion droplets that physically link cDNA of multiple transcripts for subsequent 
viii 
 
analysis by high-throughput DNA sequencing.  Experimental throughput of over 2x10
6
 
cells in a single day with antibody heavy and light chain pairing accuracy greater than 
97% was demonstrated with in vitro expanded human B cells.  These new single-cell 
sequencing technologies were also applied for rapid discovery of new human antibodies 
and for analysis of the human immune response to vaccination.  Finally we applied the 
techniques developed here to gain new insights regarding development of the antibody 
repertoire through high-throughput and high-resolution examination of naïve and 
memory B-cell compartments in healthy human donors. 
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1. BACKGROUND
1.1  Antibodies and Antibody Repertoire Development 
Antibodies are Y-shaped molecules produced by the immune system of many 
vertebrates to recognize and neutralize foreign pathogens with high specificity.  An 
antibody molecule is comprised of two major portions:  the constant region (or Fc 
region), which is identical among different antibody molecules having different 
specificities, and the variable region, which comprises a unique sequence for each 
antibody and is responsible for antigen recognition (Figure 1.1).  Different antibody 
variable regions confer different antibody binding specificities, and binding specificity is 
encoded by the unique antibody amino acid sequence (which in turn is encoded by the 
respective immunoglobulin genes). Binding to molecular targets occurs at the exposed 
ends of the variable region.  
The antibody variable region can be further subdivided into framework regions 
and complementarity-determining regions (Figure 1.1). The relatively conserved 
framework regions (FRs) consist of antiparallel β strands which form a β-sandwich 
structure called the immunoglobulin fold
8
.  Within the antibody variable region are
several areas of higher variability which are termed the complementarity-determining 
regions (CDRs), or hypervariable loops.  The CDRs contain much higher variation across 
different antibodies than the more conserved FRs.  The precise area of the variable region 
where antibody binding occurs is called the paratope, and the complementary binding 
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region on an antibody’s molecular target is termed the epitope.  CDRs often comprise the 
antibody paratope. 
In addition to the specificity conferred by the antibody variable region, antibody 
functionality is further determined by the type of antibody constant region (Figure 1.1), 
termed the antibody class or isotype.  Five major classes of antibody constant regions 
exist (IgD, IgM, IgG, IgA, and IgE), and several contain subclasses as well (e.g. IgG1, 
IgG2, IgA1, IgA2, etc.)  Each antibody class and sub-class performs different functions 
in terms of conferring protection against pathogen challenge.  For example, IgM is 
expressed early in B cell development, is secreted as a pentamer, and excels at activating 
immune complement (or the killing of pathogenic cells via activation of innate immune 
response mechanisms), whereas human IgG is expressed later in B cell development, is 
secreted as a monomer and is a less potent activator of complement.  An overview of 
antibody isotypes is presented in Table 1.1. 
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Figure 1.1 An overview of antibody structure.  Antibodies are Y-shaped molecules 
which consist of a variable region that imparts binding specificity and a 
constant region that determines the functionality of the antibody molecule.  
The variable region is further subdivided into framework regions (FRs) 
which are somewhat conserved across antibodies, as well as 
complimentarity-determining regions (CDRs) which are highly variable 
across different antibodies. The variable and constant regions are comprised 
of both heavy chain and light chain genes.  The heavy chain variable region 
is comprised of the recombined VH-DH-JH genes, whereas the light chain 
variable region is composed of recombined VL-JL genes.  Reproduced with 
permission of the Nature Publishing Group
2
.
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Isotype 
Secreted 
form 
Molecular 
weight (kDa) 
Serum conc. 
(mean adult 
mg/mL) 
Serum 
half-life 
(days) 
IgD monomer 188 0.03 3 
IgM pentamer 970 1.5 10 
IgG1 monomer 146 9 21 
IgG2 monomer 146 3 20 
IgG3 monomer 165 1 7 
IgG4 monomer 146 0.5 21 
IgA1 dimer 160 3.0 6 
IgA2 dimer 160 0.5 6 
IgE monomer 188 5.E-05 2 
Table 1.1  Overview of antibody constant regions, adapted from
9
.
 Membrane-bound B-cell receptors (BCR), the form of antibodies that is 
expressed on the surface of B cells, are assembled via somatic recombination of antibody 
V-, (D-,) and J-genes within developing B cells in the bone marrow (Figures 1.1 and 
1.2)
2,9
.  Antibody variable region gene recombination is mediated by the recombination
activating genes (RAG-1 and RAG-2).  The RAG enzymes recognize nucleotide patterns 
in the genome known as recombination signal sequences (RSS)
9
.  Expression of RAG
genes is highest during the pro-B and pre-B stages when V-(D)-J recombination occurs. 
RAG recombination can also generate junctional diversity at single-stranded DNA break 
sites via p-nucleotide addition and junctional trimming.  Another critical enzyme for B 
cell development is terminal deoxynucelotidyl transferase (TdT), which is a specialized 
polymerase that is expressed predominantly during heavy chain rearrangement at the pro-
B stage, and some expression can also occur in pre-B cells.  TdT adds non-templated 
nucleotides to the D-J and V-J junctions, thereby dramatically increasing the junctional 
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diversity formed by recombination.  The higher expression of TdT during heavy chain 
formation causes much broader variation in the length of heavy chain CDR3 loops 
(which comprise the VH-DH-JH genes) because TdT adds a random number of nucleotides 
in each junction (typically, 0-30 nt per junction).  Low expression of TdT in pre-B cells 
and the lack of a D-gene causes light chain CDR3 loop lengths to be fairly restricted
9
.
The B cell receptor heavy chain variable region is comprised of three genes: a VH 
gene, DH gene, and a JH gene, and the site of heavy chain recombination is fully 
contained by the CDR-H3 (Figure 1.1).  In contrast, the light chain comprises a VL gene 
and a JL gene, and the VL-JL junction is contained within the CDR-L3 (Figure 1.1).  After 
a stem cell differentiates into a pro-B cell, the pro-B cell rearranges first the heavy chain 
DH-JH junction, then recombines the DH-JH product with a VH-gene to form the VH-DH-JH 
region, with all recombination events mediated by RAG expression.  Recombination is 
stopped when the newly formed heavy chain paired with a surrogate light chain are both 
expressed on the cell surface.  (The surrogate light chain covers the newly-generated 
heavy chain variable region to prevent aberrant B-cell receptor binding.)  This important 
step ensures that a productive, in-frame heavy chain junction without stop codons has 
been generated because RAG and TdT have no innate mechanism to maintain amino acid 
reading frames and thus only one in every three V-(D-)J recombinations will yield a 
productive sequence.  After surface expression of the heavy chain, TdT expression 
sharply decreases and the B cell is now denoted as a pre-B cell.  At this stage, pre-B cells 
with newly formed heavy chains undergo a pre-B expansion that consists of up to eight 
cell divisions that create multiple B cell clones with the same heavy chain
10
 (observed
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directly in mice, inferred in humans).  Next, light chain VL-JL recombination occurs in the 
expanded pre-B cells in a similar manner as heavy chains recombined using the RAG 
enzyme, but with very low levels of TdT expression that lead to generally restricted light 
chain CDR-L3 lengths
9
.  As in pro-B cells, the final checkpoint to continue development
after the pre-B stage consists of surface immunoglobulin display, this time with the 
somatically generated heavy and light chains together.  RAG expression and light chain 
recombination ceases, and the cell is termed an immature B cell. 
Next, immature B cells undergo an immune tolerance checkpoint to ensure that 
autoreactive antibodies do not continue in the antibody maturation pathway, as the 
process of random gene recombination without functional selection can generate self-
reactive proteins.  Tolerance checkpoints are thought to occur by clonally deleting B cells 
encoding BCRs that bind to self-proteins, or alternatively, receptor editing can rescue 
self-reactive B-cells at this stage
11
.  A known hallmark of autoreactivity is the expression
of a very long heavy chain CDR-H3 loop, and BCRs with long CDR-H3s are 
preferentially deleted from the repertoire during the pre-B tolerance checkpoint
12
.  After
passing tolerance checkpoints, the B-cell expresses both IgD and IgM constant regions as 
B-cell receptors on the cell surface and is considered a mature, or naïve, B cell.  The 
newly generated mature B cell is now ready for positive selection in germinal center 
reactions of the spleen and lymph nodes in the course of an immune response. 
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Figure 1.2 The sequential stages of B cell development.  Central immune tolerance 
checkpoint occurs after immature B cells are formed, and autoreactive B 
cells are clonally deleted or edited before continuing to become mature 
(naïve) B cells.  Copyright 2011 from Janeway's Immunobiology, 8th 
Edition by Murphy.  Reproduced by permission of Garland Science/Taylor 
& Francis LLC
9
.
1.2  Immune responses lead to B-cell activation and antibody secretion 
One of the first steps in the immune response is the ingestion of pathogenic cells 
by macrophages via macro-pinocytosis which then migrate to the spleen and tissue-
draining lymph nodes (collectively called the secondary lymphoid organs)
9
.  There,
macrophages mature into specialized antigen-presenting cells (APCs) named follicular 
dendritic cells that present captured foreign proteins to B- and T-cell surveillance.  
During follicular dendritic cell antigen presentation, peptides from digested foreign 
proteins are presented on the cell surface in the major histocompatibility complex 
(MHC), a specialized cell surface protein for display of peptides to T cells.  T cells 
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survey MHC using their somatically generated T-cell receptors, or TCR.  TCR are 
formed in a very similar process to BCR, with the notable difference that T cells do not 
normally express AID and therefore TCR do not exhibit somatic hypermutation or class-
switch recombination
9,13
.  If a T cell’s TCR binds tightly to a peptide presented on MHC
by APCs during the course of infection, the T cell will be given signals to expand and 
proliferate by the follicular dendritic cell. Known activating signals include a 
combination of the secreted cytokines like IL-6, IL-12, and TGF-β, and especially the B7 
co-receptors which bind to CD28 (activating) and CTLA-4 (inhibiting) receptors on the 
T-cell surface.  If a naïve T cell recognizes its peptide antigen in the absence of 
professional antigen-presenting cell co-receptor signals, the T cell will undergo 
functional inactivation or clonal deletion.  The requirement for dedicated APCs to 
mediate T-cell activation is a key immune control mechanism that minimizes 
autoimmunogenic T-cell proliferation and ensures that T-cell activation occurs only as a 
result of the response to infection mediated by APCs. 
Effector T cells comprise two major classes: 
1. CD8
+
 cytotoxic T cells: bind MHC class I proteins expressed on all cells in the
body and and survey cytosol (endoplasmic reticulum-derived) proteins. 
2. CD4
+
 helper T cells: bind MHC class II proteins that are expressed only on
dedicated antigen-presenting cells (e.g. follicular dendritic cells and B cells) 
and survey vesicular (extracellular-derived) proteins. 
CD8
+
 effector T cells (or cytotoxic T lymphocytes, CTLs) are cytotoxic cells that
clonally expand and survey cells in the body for signs of infection.  When CD8 T cells 
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identify another cell expressing its targeted foreign peptide-MHC (e.g. a viral peptide 
from a virally infected cell) the CTL kills the target cell or induces the target cell to 
undergo programmed cell death and thereby eliminate the infection.  As MHC class I is 
expressed by all cells in the body and constantly presents peptides derived from inside the 
cell onto the cell surface, CTLs can survey ongoing protein expression in all cells and 
tissues and are the main effector cell against intracellular pathogens.  Alternatively, CD4
+
T cells are activated by follicular dendritic cells to become helper T cells and remain in 
secondary lymphoid organs.  CD4
+
 T cells perform a critical role in enabling the antibody
(or extraceullar) immune response.  The five major CD4 effector T subclasses (TFH, TH1, 
TH2, TH17, and Treg) are summarized in Table 1.2. 
CD4 effector 
subset APC 3rd signal Subset  function 
TFH IL-6 B cell activation 
TH1 IL-12 + IFN-γ Intracellular bacterial response 
TH2 IL-4 
Parasitic response (eosinophils, mast cells, 
IgE B cell activation) 
TH17 TGF-β + IL-6 
Extracellular bacteria/fungi, induce 
epithelial/stromal cells to secrete cytokines 
for neutrophil recruitment 
Treg TGF-β 
Suppress T-cell activity, prevent 
autoimmunity 
Table 1.2 Overview of CD4
+
 T cell effector subsets.  Each subset is induced from naïve
T cells via a unique third signal provided by antigen presenting cells (Signal 
1 comprises the TCR-peptide-MHC interaction, and Signal 2 consists 
mainly of CD28-B7 interactions)
9
.
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Naïve B cells are activated by both antigen-presenting cells and CD4
+
 helper T
cells (specifically, TFH cells, see Table 1.2).  B cell selection occurs in germinal center 
(GC) reactions of the spleen and lymph node (Figure 1.3)
9,14
.  In germinal centers, B cells
that encode BCR will bind to antigen presented on follicular dendritic cells.  Following 
receptor endocytosis of the BCR bound to antigen, the B cells digest proteins and display 
the resulting peptides on MHC class II on the B cell surface.  CD4
+
 follicular helper T
(TFH) cells that have been activated by follicular dendritic cells will in turn induce those 
antigen-specific B cells to activate via the TCR-peptide-MHC contacts combined with 
interactions between the B cell co-receptor CD40 and the T-cell CD40 ligand (CD40L, or 
CD154).  CD4 helper T-cells secrete cytokines that stimulate B cell proliferation and 
differentiation such as IL-4, IL-5, and IL-6. 
When naïve B-cells receive the proper signals from antigen-specific T cells, those 
B cells are activated to undergo somatic hypermutation mediated by the enzyme 
activation-induced cytidine deaminase (AID) that is linked to successive rounds of cell 
division in the dark zone of the GC reaction
15
 (Figure 1.3).  Further rounds of positive
selection in the light zone successively enhance antibody affinity to the antigen of 
interest
16
.  Activated B cells can also undergo class-switch recombination, also mediated
by AID, which alters the antibody class via genomic deletion of IgM/IgD constant 
regions to change the antibody isotype to IgG, IgA, or IgE.  Positive selection in the GC 
light zone induces B cells to asymetrically proliferate into a combination of antigen-
secreting plasmablasts, antigen-secreting plasma cells, and memory B cells, which 
comprise the effector cells of the antibody response
17
.
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Figure 1.3 Overview of germinal center reactions where B cell selection, affinity 
maturation, and class-switching occurs.  Naïve B cells uptake antigen from 
follicular dendritic cells and present peptides in MHC class II on their cell 
surface, and CD4 follicular helper T (TFH) cells specific to those peptides 
induce B cell activation.  B cell activation induces migration to the dark 
zone for clonal expansion and expression of AID for somatic hypermutation 
and possibly class-switch recombination, followed by return to the light 
zone for successive rounds of affinity maturation.  B cells with 
disadvantageous mutations will not acquire more antigen from DCs and will 
apoptose, whereas B cells with improved affinity will undergo additional 
selection including return to the dark zone for additional proliferation, SHM, 
and class-switching.  Activated naïve B cells mature into the effector B cells 
of the serum antibody response (plasmablasts, plasma cells, and memory B 
cells).  Reproduced with permission of the Nature Publishing Group
18
.
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Importantly, other pathways exist for B cell activation beyond germinal center 
reactions.  B cell maturation has also been reported at the border of the splenic T cell 
zone and red pulp
19
, and for some antigens (termed T-independent antigens) B cell
activation can occur in the absence of T-cell help.  T-independent antigens often have a 
component that triggers a receptor of the innate immune system on the B cell surface, or 
alternatively can extensively cross-link IgM BCR molecules on the B cell surface
9
.
While some antigens are able to induce antibody responses in the absence of T-cell help, 
the vast majority of proteins will not be able to activate the B cell response in the absence 
of CD4
+
 T-cell assistance.
The three B effector cell subsets (plasmablasts, plasma cells, and memory B cells) 
each have a distinct role in fighting disease.  Plasmablasts are short-term mediators of 
serological immunity; they secrete high levels of antibody and circulate in peripheral 
blood for a relatively limited amount of time (days) before undergoing apoptosis, 
resulting in a rapid increase in antibody concentration in serum that dissipates according 
to serum antibody half-life (approximately two weeks)
20,21
.  Similar to plasmablasts,
plasma cells (PCs) also secrete antibody but are long-lived and home to bone marrow 
where they can persist for many years
22–25
 and continuously secrete high levels of
immunoglobulin (estimated at 10,000-20,000 molecules/cell-sec)
2
.  Long-term
serological memory is mediated by the plasma cell populations residing in the bone 
marrow.  Like plasma cells, memory B cells are also long-lived but do not secrete 
antibody.  Instead, memory B cells express immunoglobulin as a B-cell receptor on their 
cell surface and circulate in peripheral blood (and pass through secondary lymphoid 
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organs) until encountering its cognate antigen again.  Upon re-encounter with their 
specific antigen, memory B cells rapidly differentiate into plasmablasts and/or plasma 
cells to enable long-term immune memory, and the kinetics of memory B cell activation 
(or secondary responses) are much faster than the first (or primary) response to a 
particular antigen.  A comparison of various B-cell subset characteristics with relevance 
to antibody repertoire sequence analysis is provided in Table 1.3.   
Germinal center B cell activation results in a variety of high-affinity antibodies 
specific to a target antigen.  The resulting effector B cell clones can persist for a very 
long time (e.g. nearly 90 years in the case of memory B cells
26
), and the entire collection 
of antibodies encoded by a particular individual resulting from a lifetime of immune 
responses comprise that individual’s antibody repertoire.  Given the large number of 
unique B cell clones in humans (likely exceeding 2x10
6
 unique antibodies in peripheral 
blood alone
27,28
), a comprehensive analysis of the antibody repertoire requires high-
throughput data collection and analysis.  Beginning in 2008, the rapidly falling costs of 
gene sequencing for the first time permitted economic repertoire-scale, high-resolution 
DNA sequence analysis of B-cell populations (Figure 1.4).  These new experimental 
techniques, collectively known as high-throughput sequencing or next-generation DNA 
sequencing, are fundamentally transforming our B- and T-cell analytical methods and our 
understanding of adaptive immune responses. 
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Repertoire subset Selection mechanisms Isotypes SHM? 
Mature (naïve) B cell Negative IgM/IgD No 
Memory B cell Positive and Negative IgM,IgG,IgA,IgE Often 
Plasmablast/plasma cell Positive and Negative IgM,IgG,IgA,IgE Often 
Table 1.3 Selected characteristics of B-cell subsets relevant to antibody repertoire 
sequence analysis.  B cells are negatively selected in central and peripheral 
tolerance, and positively selected for antibody affinity to antigen in GC 
reactions. 
1.3  High Throughput Antibody Sequencing 
Tremendous advances in the economics of next-generation DNA sequencing 
technologies over the last six years have dramatically accelerated the pace of biological 
research (Figure 1.4).  High-throughput DNA sequencing has been a transformative 
method for studying adaptive immunity by permitting repertoire-scale analysis of the vast 
number of unique BCRs and TCRs in the adaptive immune system
2,29
.  Exact
measurement of total human B cell repertoire size has remained difficult to determine 
because of tissue sampling limitations (peripheral blood, bone marrow, and secondary 
lymphoid organs), combined with high-throughput sequencing error (typically ~0.5% of 
sequenced bases
30,31
) that contribute noise to secondary data analysis.  However, lower-
bound estimates of repertoire size are approximately 2x10
6
 unique B cell clones
(expressing distinct BCRs) in peripheral blood alone
27,28
.  Upper bounds on repertoire
size are difficult to estimate but are several orders of magnitude higher, with theoretical B 
cell receptor diversity exceeding 10
13
 and individual limitations at around 10
11
 B cells in
the human body
2,9,32,33
.
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Figure 1.4 High-throughput DNA sequencing costs have dropped dramatically in recent 
years beginning with the introduction of the first next-generation sequencing 
platforms in 2008
34
.  Log-scale reductions in DNA sequencing costs have
directly enabled high-throughput analysis of individual antibody repertoires.  
New high-throughput DNA sequencing methods are fundamental drivers of 
recent advances in antibody repertoire sequencing and antibody discovery. 
Standard immune repertoire high-throughput sequencing protocols begin with 
collection of 10
3
-10
7
 lymphocytes, followed by cell lysis and recovery of cellular mRNA.
Next, mRNA is reverse transcribed and a PCR multiplex primer set which targets all 
known V-genes is used for PCR amplification of antibody or TCR genes.  In the case of 
antibody analysis, the 5’ PCR primers are usually designed to target V genes, while the 3’ 
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primers target either the J genes or constant regions (e.g. IgG, IgA, etc.) for sequence 
analysis of the entire antibody variable region (Figure 1.1)
2
.  (Some protocols omit V-
gene-specific primers and incorporate RACE PCR to reduce PCR amplification bias
35
.)
For antibody analysis, the heavy chain, kappa light chain, and lambda light chains are 
each amplified in separate PCR reactions. Finally, high-throughput sequencing and 
bioinformatic analysis are performed to quantitatively determine the composition of the 
input immune repertoire encoded by the cells originally isolated from experimental 
samples
2,31,36,37
.  High-throughput repertoire sequencing has been applied in a variety of
applications ranging from characterization of the repertoire in healthy and disease 
states
38–41
, to analysis of antibody-pathogen interactions
7,42,43
, to rapid antibody
discovery
4,42
.
Despite the tremendous recent advances, all currently available techniques for 
antibody repertoire analysis have one severe limitation:  high-throughput antibody 
sequencing techniques performed to date are unable to resolve the pairing between 
antibody heavy and light chains.  Using the high-throughput sequencing methods 
described above, B cell populations are lysed in bulk to collect mRNA for downstream 
sequence analysis.  Recombined heavy and light V-(D-)J junctions are located on 
separate chromosomes and expressed as distinct mRNA strands, and the bulk B cell lysis 
required for high-throughput sequencing confounds the pairing between heavy and light 
mRNAs expressed by individual B cells.  Next-generation sequencing techniques can 
sequence only one mRNA strand at a time, which further complicates efforts to preserve 
heavy and light chain pairing information
2,5–7
.  Without the ability to analyze paired
17 
heavy and light chain sequences at single-cell resolution, the full antibody clonotype 
(both heavy and light chains) cannot be resolved, nor can the resulting antibody 
sequences be expressed to test for function nor modeled computationally. 
1.4 Monoclonal Antibody Discovery Methods 
The utility of serum antibodies for treating disease was first established in the late 
19
th
 century through the work of Emil von Behring, Kitasato Shibasaburo, and Emile
Roux in developing serum therapies to diphtheria toxins.  These early methods were 
based on polyclonal antibodies, or a mixture of all the different antibody specificities 
contained in human or animal sera.  Research continued with polyclonal antibody 
mixtures until the 1970’s when Georges Köhler and César Milstein published a method to 
generate hybridomas, or a B cell fused with an immortalized myeloma cell that allowed 
the resulting cell hybrid (called a hybridoma) to secrete antibody continuously in 
culture
44
.  The discovery of hybridomas ushered in a new era of biotechnology as
monoclonal antibodies (mAbs) against a wide variety of antigens could be isolated from 
mice following challenge with the antigen of interest.  
In the hybridoma process, B cells and myeloma cells are fused as described 
above, then cells are divided into individual wells by limiting dilution and cultured as 
they produce and secrete antibody.  Culture supernatant from each well containing 
secreted antibody is screened for binding to antigen via enzyme-linked immunosorbent 
assay (ELISA), and cells from any positive-binding wells can be retrieved, further 
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expanded, cloned, and sequenced, while the monoclonal antibody itself can also be 
purified from hybridoma culture supernatant.  Hybridoma methods continue to have 
tremendous impact; the basic techniques were outlined almost 40 years ago and are still 
relevant today, but hybridoma techniques have improved such that an antibody can be 
developed toward a particular target much more quicklky and with high reliability.  In 
particular, recent key methods include enhancing the efficiency of hybridoma generation 
with human cells
45
 and humanization of mouse antibodies or the development of human
transgenic
46–49
 or humanized
50–52
 mouse models to reduce antibody immunogenicity of
the resulting monoclonal antibody therapeutics.  Several protocols have also permitted 
faster and more economical hybridoma screening to accelerate the discovery of human or 
humanized monoclonal antibodies
53–55
.  In particular, transgenic mice have recently been
used for isolating human monoclonal antibodies against human proteins (the response to 
self-antigen is limited in humans), and resulting mAbs can be used to agonize or block 
human surface receptors or target expressed oncogenes for cancer therapeutics.  However 
despite tremendous advances in tried-and-true hybridoma technologies, mAb discovery 
via hybridomas remains time-consuming and expensive due to the single-cell limiting 
dilution needed and the time required hybridomas to adequately expand from a single cell 
to a cell population (several weeks).  The large number of culture supernatant screens 
required also make hybridoma mAb discovery an extremely resource-intensive 
experimental technique.  
An important alternative technology to hybridoma mAb discovery is antibody 
isolation via the screening of combinatorial libraries. The most widely used 
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combinatorial library discovery platform technology employs display on M13 bacterial 
phage, where antibody variable regions are PCR amplified from B cell populations of 
interest and expressed for display on the surface of bacteriophage.  Then, the phage can 
be selected for binding to the surface of antigen-coated plates or tubes, and bound phage 
are eluted from tubes and amplified via re-infection of bacteria (with mutations acquired 
in each round).  Finally after several rounds of phage panning a high-affinity monoclonal 
antibody can be isolated
56–62
.  Phage panning has several key advantages including lower
cost and the capability to affinity mature antibodies in vitro, however phage panning 
library construction requires combinatorial shuffling of heavy and light chain pairs during 
library generation, leading to a non-natural (synthetic) antibody library.  Another major 
limitation to phage panning is that the resulting antibodies have not been screened by 
central or peripheral tolerance checkpoints in the immune system.  Thus while it is a 
highly effective method for isolation of research and diagnostic antibodies, phage 
panning’s inability to isolate native heavy and light chain pairings and the accrual of 
mutations throughout phage panning pose risks for immunogenicity and off-target 
binding in humans, and phage panning has limited applications for therapeutic antibody 
discovery
63
.
A more recent method for monoclonal antibody discovery has applied high-
throughput sequencing of B cell receptors to identify antibodies of interest
4,7,64
.  Antibody
discovery via high-throughput sequencing is rapid and efficient, and it also provides 
information on the entire repertoire of antibodies elicited in the individual.  High-
throughput sequencing of the cellular repertoire can also be used to construct a database 
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for proteomic analysis of human serum antibodies via mass spectrometry
35,65–68
.   These
techniques quantify the serum antibodies generated in response to vaccination and 
disease and have proven useful for antibody discovery by linking antibody function (i.e. 
binding to a particular antigen) to the antibody sequence
65,66,69
.  High-throughput and
proteomic techniques for antibody discovery will become more widely used in the 
coming years as DNA sequencing costs decrease further. 
The major limitation to any high-throughput sequencing antibody discovery 
approach is that, similar to phage panning, the library of heavy and light chains must be 
shuffled prior to antibody expression because heavy and light chain pairing information is 
irreversibly lost during high-throughput sequencing
5–7
.  High-throughput approaches
could be optimal for antibody discovery and immune repertoire analysis if a new 
technology were available to gather single-cell heavy and light chain pairing information 
at high-throughput.  The state of current (low-throughput) sequence-based alternatives to 
high-throughput sequencing, collectively known as single-cell RT-PCR, and applications 
of single-cell sequencing to antibody discovery are discussed in the following section. 
1.5  Single-Cell Sequencing Techniques 
As mentioned above, existing immune repertoire high throughput sequencing 
technologies yield data on only one of the two chains of immune receptors and cannot 
provide information about the identity of immune receptor pairs encoded by individual B 
or T lymphocytes
5–7
.  Because of this major limitation, lower-throughput single-cell
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techniques must be used when paired heavy and light chain information is required.  
Several experimental techniques have been employed for detection or sequencing of 
genomic DNA or cDNA from single cells; however these techniques are limited by low 
efficiency or low cell throughput (<200-500 cells) and further, they require fabrication 
and operation of complicated microfluidic devices
70–74
.  Due to these limitations,
sequence analysis of VH:VL pairs is currently performed by microtiter-well sorting of 
individual B cells followed by single-cell RT-PCR (scRT-PCR) and Sanger 
sequencing
5,12,75–77
.  Once the sequence of a B cell has been isolated it can be cloned into
bacteria and tested for antigen binding to a protein of interest
75,76,5,78
, or alternatively each
B cell can be induced to secrete antibody in vitro prior to screening single-cell culture 
supernatant by microneutralization
79
.  A significant time savings can also be achieved via
linkage of heavy and light chains in the RT-PCR, thereby reducing cloning steps by a 
factor of two
75,80,81
.
Single-cell sequencing in the small volumes that are required for high-throughput 
experiments is severely limited by inhibition of the RT-PCR reaction by cell lysate, 
which poses a lower bound on microwell or droplet volume at around 5 nL/cell for one-
pot cell encapsulation and RT-PCR
72
.  Incomplete cell lysis and RNA degradation during
thermal cell lysis can further reduce yield of linked cDNA products.  Furthermore, cell 
lysis and mRNA recovery steps are non-trivial to perform at high-throughput and with 
single-cell fidelity.  These experimental complications have made high-throughput 
sequencing of multiple mRNA transcripts from single cells a critical unsolved problem.  
Thus, potential solutions for sequencing of multiple mRNA strands derived from single 
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cells would have important applications for in-depth analysis of antibody and TCR 
repertoires as well as provide a tremendous boost to currently available antibody 
discovery techniques
2,5–7
.
1.6  Synopsis 
This dissertation directly addresses the limitations of currently available high-
throughput methods in resolving heavy and light chain pairings via the development and 
application of new high-throughput, single-cell sequencing technologies.  In Chapter 
Three (High-throughput sequencing of the paired human immunoglobulin heavy and light 
chain repertoire)
82
, we report a new method for sequencing B cell heavy and light chains
at single-cell resolution by capturing cells in micropatterned PDMS wells and lysing cells 
individually, with the capacity to analyze up to 5x10
4
 B cells in a single experiment.
After validating our technique, we analyzed human antibody responses in healthy and 
vaccinated donors and applied our high-throughput paired heavy and light chain 
sequencing platform for human antibody discovery. 
Next, Chapter Four (In-depth determination and analysis of the human paired 
heavy and light chain antibody repertoire)
83
 relates a modification of the single-cell
sequencing methods described in Chapter Three that provided greatly enhanced cell 
throughput.  We constructed and validated a new flow-focusing nozzle system for single 
B cell isolation and analysis with the capacity to emulsify up to 3x10
6
 B cells per hour.
After demonstrating that our technique was >97% accurate by analyzing technical 
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replicates of expanded B cell populations, we characterized several previously unreported 
features of human antibody repertoires including a quantitative analysis of promiscuous 
and public light chain junctions (i.e. light chains expressed by multiple B cell clones both 
within and across human donors) and the high-throughput detection and sequence 
characterization of allelically included human B cells. 
The fifth chapter of this report (Paired VH:VL analysis of naïve B cell repertoires 
and comparison to antigen-experienced B cell repertoires in healthy human donors) 
applied the new high-throughput techniques developed in Chapters Three and Four 
toward a comprehensive, high-resolution analysis of naïve and antigen-experienced B 
cells in the same individuals.  Comprising the first high-throughput analysis of heavy and 
light chains to compare multiple B cell compartments, our analysis of gene usage and 
antibody biochemical composition generated new insights regarding antibody 
development, maturation, and selection processes across several human donors. 
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2. HIGH-THROUGHPUT SEQUENCING OF THE PAIRED HUMAN
IMMUNOGLOBULIN HEAVY AND LIGHT CHAIN REPERTOIRE1 
2.1 Rationale and Supporting Information  
Currently existing immune repertoire sequencing technologies yield data on only 
one of the two chains of immune receptors
5–7
.  Sequence analysis ofVH:VL pairs is
currently performed by microtiter-well sorting of individual B cells followed by single-
cell RT-PCR (scRT-PCR) and Sanger sequencing
5,12,75–77,84–86
; however at most a few
hundred VH:VL pairs (a number dwarfed by the enormous size of the human antibody 
repertoire) are identified via scRT-PCR
76,77,84,85
.  Microfluidic methods for RT-PCR and
the sequencing of two or more genes (for example using the Fluidigm platform
87
), have
so far been limited to only 96 wells per run and require complex, proprietary 
instrumentation.  As a result, comprehensive analysis of paired VH:VL gene family usage 
and somatic hypermutation frequency has been elusive. 
1 DeKosky, B. J. et al. High-throughput sequencing of the paired human immunoglobulin heavy and light 
chain repertoire. Nat. Biotechnol. 31, 166–169 (2013).  B.J.D. and G.G. developed the methodology and 
designed the experiments. B.J.D., G.C.I. and G.G. wrote the manuscript; B.J.D., G.C.I., R.P.D., J.J.L., 
Y.W., B.M.R., C.G. and S.F.A. performed the experiments; B.J.D. carried out the bioinformatic 
analysis; S.P.H.-S. performed Illumina sequencing; G.C.I., N.V., T.D., P.C.W., C.G.W. and A.D.E. 
helped design experiments; B.J.D., G.C.I., J.J.L., Y.W., S.P.H.-S., A.D.E. and G.G. analyzed the data. 
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Several prior studies have analyzed single cells by first isolating the cells into 
high-density microwell arrays
54,88–91
.  Such methods have been used for phenotypic and
genomic sequence analyses of cells at high throughput, however mRNA sequence 
analysis is complicated by inhibition of reverse transcription by cell lysate at 
concentrations germane to cell isolation in microwell arrays
72
.  We reasoned that a
system capable of selectively capture mRNA from single cells could circumvent cell lysis 
inhibition of the RT-PCR reaction by first permitting cell lysis under the harsh conditions 
which preserve mRNA (e.g. the presence of dodecyl sulfate and DTT to inactivate 
endogenous RNAse), and single-cell mRNA could then be purified for use as RT-PCR 
template.  Magnetic beads could be used as the mRNA capture agent by utilizing 
poly(dT) oligonucleotides conjugated to the magnetic beads to bind to the polyadenylated 
mRNA tail.  Magnetic beads are also compatible with a variety of downstream processing 
steps like emulsion RT-PCR, which obviates the need to intentionally release mRNA 
from the beads and therefore the microbeads would never need to be removed from the 
sample.  We also reasoned that by linking VH and VL transcripts onto a single strand 
(similar to previously published methods
75
), we could sequence paired VH and VL chains
using standard next-generation sequencing protocols. 
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Methodology: 
Figure 2.1 Overview of the high throughput methodology for paired VH:VL antibody 
repertoire analysis.  (a) B-cell populations are sorted for desired phenotype 
(mBCs=memory B cells, naive B=naive B cells).  (b) Single cells are 
isolated by random settling into 125 pL wells (56 μm diameter) printed in 
polydimethylsiloxane (PDMS) slides the size of a standard microscope slide 
(1.7x10
5
 wells/slide).  2.8 μm poly(dT) microbeads are also added to the
wells (average 55 beads/well).  (c) Wells are sealed with a dialysis 
membrane and equilibrated with lysis buffer to lyse cells and anneal VH and 
VL mRNAs to poly(dT) beads (blue figure represents a lysed cell, orange 
circles depict magnetic beads, black lines depict mRNA strands.  (d) Beads 
are recovered and emulsified for cDNA synthesis and linkage PCR to 
generate an ~850 base pair VH:VL cDNA product (Figure A1.1).  (e) Next 
Generation sequencing is performed to sequence the linked strands.  (f) 
Bioinformatic processing is used to analyze the paired VH:VL repertoire. 
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As shown in Figure 2.1, a population of sorted B cells is deposited by gravity into 
125 pL wells molded in polydimethylsiloxane (PDMS) slides.  Each slide contains 
1.7x10
5
 wells; four slides processed concurrently accommodate 68,000 lymphocytes at a
≥1:10 cell:well occupancy which gives at least a 95% probability of only one cell per 
well based on Poisson statistics.  Poly(dT) magnetic beads with a diameter of 2.8 μm are 
deposited into the microwells at an average of 55 beads/well and the slides are covered 
with a dialysis membrane.  Subsequently the membrane-covered slides are incubated with 
an optimized cell lysis solution containing 1% lithium dodecyl sulfate that results in 
complete cell lysis within <1 minute.  The mRNA anneals to the poly(dT) magnetic 
beads which are then collected, washed, and emulsified with primers, reverse 
transcriptase, and thermostable DNA polymerase to carry out reverse transcription 
followed by linkage PCR (Figure A1.1).  The two-step capture and amplification process 
(Fig. 3.1) is necessary because single-compartment cell lysis followed by RT-PCR has 
not proven feasible in volumes ≤5 nL due to inhibition of the reverse transcription 
reaction by cell lysate constituents, and because performing VH:VL linkage in emulsion 
droplets at the single cell level would necessitate cell entrapment, lysis, reverse 
transcription, and in situ linkage PCR that can only be performed in microfluidic devices, 
a strategy which requires extensive infrastructure and so far has been reported to have 
limited throughput at ≤300 cells per run72.  PCR amplification as outlined in Figure A1.1
generates an ~850 base pair (bp) linked VH:VL DNA product composed of (from 5’ to 
3’) the N-terminal end of CH1, the VH, a linker region, the VL and the N-terminal of C 
or CThe most informative 500 bp of this fragment which encompasses the 
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complementarity determining regions (CDR-H3 and CDR-L3) is then sequenced on a 
long-read next generation sequencing platform such as the 2x250 Illumina
TM
 MiSeq
(which also provides the framework region FR3 and FR4 sequences and constant region 
N-termini amino acid sequences that can be used for isotype assignment).  If FR1 to 
CDR2 region sequences are also desired, the VH and VL gene repertoires are analyzed 
by separate 2x250 bp sequencing runs.  This latter step is required because of read length 
limitations with existing technology; while single molecule sequencing techniques allow 
for longer reads the error rate is currently too high to enable robust classification of 
VH:VL sequences. 
2.2 Results: 
We employed the methodology of Figure 2.1 to determine the VH:VL repertoire 
of three different B-cell populations of relevance to human immunology and antibody 
discovery.  First, we isolated IgG
+
 B cells from fresh blood donated by a healthy
individual.  61,000 IgG
+
 B cells were spiked with immortalized IM-9 lymphoblast cells
(to approximately 4% of total mixture) that express known VH and VL sequences as an 
internal control.  We analyzed these cells in four PDMS slides (6.8x10
5
 total wells).
After 2x250 MiSeq sequencing, we clustered the CDR-H3 regions based on 96% 
sequence identity, consistent with the established error rate of the MiSeq platform, to 
determine the number of unique clones recovered from this human sample.  A total of 
2,716 unique pairs were thus identified (Table A1.1).  The spiked IM-9 heavy chain 
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overwhelmingly (78-fold above background) paired with its known light chain.  A heat 
map shows frequencies of pairing between VH and VL segments of different germline 
families in the class-switched IgG
+ 
cell repertoire (Figure 2.2a).  A second IgG
+
repertoire analysis was performed using B cells from another anonymous individual; this 
analysis identified 2,248 unique CDR-H3 from 47,000 IgG
+ 
cells, and the IM-9 control
spike again demonstrated high pairing accuracy (125-fold above background).  Several V 
gene families (e.g. IGHV7, IGKV5, 6, and 7, IGLV4, 10, and 11) are expressed at very 
low frequencies in the human immune repertoire
52,92
.  We detected VH:VL pairs
containing these rare families, indicating that this technique can identify rare B-cell 
clones present at physiological levels together with much more abundant clones (e.g. the 
much more highly utilized IGVH3 or IGVH4 families) (Figure 2.2a).  Interestingly, 
VH:VL germline pairing frequencies were highly correlated between the two individuals 
(Spearman rank correlation coefficient=0.804, p<10
-29
); the most highly transcribed
heavy chain genes (VH3, VH4 and VH1 families) paired most frequently with the most 
highly transcribed light chain genes (V1, V3, V1 and V2).  However, putative 
differences in IgG
+
 VH:VL germline pairing frequencies between the two individuals
were also evident.
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. 
Figure 2.2 VH:VL gene family usage of unique CDR-H3:CDR-L3 pairs identified via 
high-throughput sequencing of cell populations from three different 
individuals in separate experiments using the workflow presented in Figure 
2.1:  (a) healthy donor peripheral IgG
+
 B cells (n=2,716 unique CDR3
pairs), (b) peripheral tetanus toxoid (TT) specific plasmablasts, isolated 
seven days post-TT immunization (CD19
+
CD3
-
CD14
-
CD38
++
CD27
++
CD20
-
TT
+
, n=86 unique pairs), and (c) peripheral memory B cells isolated 14 days
post-influenza vaccination (CD19
+
CD3
-
CD27
+
CD38
int
, n=240 unique pairs).
Each panel presents data from an independent experiment obtained from (a) 
61,000 fresh B cells, (b) ~400 frozen/thawed plasmablasts, (c) 8,000 twice 
frozen/thawed memory B cells. 
In a separate experiment, human plasmablasts (CD19
+
CD3
-
CD14
-
CD38
++
CD27
++
CD20
-
) from a healthy volunteer were collected 7 days after tetanus
toxoid (TT) immunization, sorted for surface antigen binding and then frozen
77
.  After
thawing, approximately 400 recovered cells were spiked with the immortalized ARH-77 
cell line as an internal control and seeded onto a single PDMS slide (1.7x10
5
 total wells).
In this instance, 86 unique primary CDR-H3:CDR-L3 pairs were identified, and the 
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ARH-77 control spike demonstrated high pairing accuracy (Fig. 3.2b, Table A1.1).  We 
expressed ten of the identified VH:VL pairs as IgG proteins in HEK293K cells.  As 
revealed by competitive ELISA, all ten antibodies showed specificity for TT and bound 
TT with high affinity (KD ranged from 0.1 to 18 nM; Table 2.1).  While certain VH 
chains can pair promiscuously with multiple VLs to yield functional antibodies, it is 
statistically implausible that 10/10 antibodies could display nM and sub-nM affinities for 
TT merely as a consequence of fortuitous VH:VL pairing.  For comparison, 10-15% of 
antibodies generated by random pairing of VH genes with a small set of enriched VL 
genes were antigen-specific
67,68
.
Antibody ID Gene Family Assignment Affinity (KD) 
TT1 HV3-HD1-HJ6 : KV3-KJ5 1.6 ± 0.1 nM 
TT2 HV3-HD3-HJ4 : LV3-LJ1 14  ± 3 nM 
TT3 HV1-HD2-HJ4 : KV3-KJ5 3.6 ± 1.8 nM 
TT4 HV2-HD2-HJ4 : KV1-KJ1 2.7 ± 0.3 nM 
TT5 HV4-HD2-HJ6 : KV2-KJ3 18 ± 4 nM 
TT6 HV1-HD3-HJ4 : KV1-KJ2 0.57 ± 0.03 nM 
TT7 HV4-HD3-HJ4 : KV1-KJ2 0.46 ± 0.01 nM 
TT8 HV3-HD3-HJ4 : LV8-LJ3 2.8 ± 0.3 nM 
TT9 HV4-HD2-HJ4 : KV1-KJ1 0.10 ± 0.01 nM 
TT10 HV1-HD3-HJ5 : KV3-KJ5 1.6 ± 0.1 nM 
Table 2.1 TT-binding affinities of IgG antibodies sequenced from TT
+
 peripheral
plasmablasts.  Peripheral blood mononuclear cells were isolated from one 
healthy volunteer 7 d after TT boost immunization and TT-binding 
CD19
+
CD3
−
CD14
−
CD38
++
CD27
++
CD20
−
 cells were sorted and analyzed as
in Figure 2.1. Genes encoding ten of the sequenced VH:VL pairs were 
cloned into an IgG expression vector and expressed transiently in HEK293F 
cells. TT-binding affinities of the resulting IgG were calculated from 
competitive ELISA dilution curves.  Each heavy and light chain was 
distinct. 
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Finally, we compared the VH:VL pairings identified using this high-throughput 
approach to those identified using the established single cell sorting method
76,93
; this
experiment was conducted in a double-blinded manner.  Peripheral CD19
+
CD3
-
CD27
+
CD38
int
 memory B cells were isolated from a healthy volunteer 14 days after
vaccination with the 2010-2011 trivalent FluVirin influenza vaccine
76
.   For the scRT-
PCR analysis, 164 single B cells were sorted into four 96-well plates, and 168 RT and 
504 nested PCR reactions were performed individually to separately amplify the VH and 
VL (kappa and lambda) genes.  DNA products were resolved by gel electrophoresis and 
sequenced to yield a total of 51 VH:VL pairs, of which 50 were unique.  A separate B-
cell aliquot from the same individual was frozen at -80°C and later thawed and processed 
using the new high-throughput approach described here.  Two PDMS slides (3.4x10
5
total wells) were used, and the sample was spiked with IM-9 cells to confirm pairing 
accuracy (Table A1.1).  A total of 240 unique CDR-H3:CDR-L3 pairs were recovered 
(Figure 2.2c).  Four CDR-H3 sequences detected in the high-throughput pairing set were 
also observed in the single-cell RT-PCR analysis.  A blinded analysis revealed that CDR-
H3:CDR-L3 pairs isolated by the two approaches were in complete agreement (Table 
A1.3).  Further, the one VH:VL pair detected in more than one of the 51 cells analyzed 
by single-cell RT-PCR was also detected in the aliquot processed by the new high-
throughput approach (clone 2D02 was observed in two cells by scRT-PCR, Table A1.3); 
these findings suggest that this B-cell clone may have undergone a great deal of 
expansion. The 46 VH genes that were each observed only once by single-cell RT-PCR 
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but that were not detected in the aliquot processed by our high-throughput approach 
presumably represent unique or very low abundance B-cell clones, as expected given the 
great degree of V gene diversity normally found in human peripheral memory B cells. 
2.3 Discussion 
In these experiments the control cell lines spiked into each aliquot of primary B 
cells were selected to approximate the levels of heavy chain and light chain transcription 
in that particular primary B-cell subpopulation. For example, the ARH-77 cell line 
expressed high levels of heavy chain and light chain transcripts and therefore was spiked 
into plasmablast populations that also express abundant heavy chain and light chain 
transcripts; in contrast, the IM-9 B lymphoblast cell line, which expresses lower levels of 
heavy chain and light chain transcripts, was spiked into memory B-cell populations. 
Known VH and VL sequences from spiked-in control cell lines were used to evaluate the 
frequency of non-native pairings, that is, the false discovery rate (FDR). The FDR, 
determined from the mispairing of spiked-in control VH and VL chains, was commensurate 
with the probability of coincident cells per well, which in turn is dictated by cell seeding 
density and follows Poisson statistics (Methods and Table A1.4). The FDR revealed by 
the mispairing frequency of control cell lines represents the upper bound of the FDR, as 
the control cell lines were introduced at levels over tenfold higher than the levels at 
which even a very highly expanded B-cell clone might be present in a biological sample 
in humans. Although currently VH:VL pairing efficiency in memory B-cell populations is 
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relatively modest (Figure 2.2 and Table A1.2), efforts to further improve efficiency are 
under way. 
The high-throughput VH:VL pairing technique described here requires one 
emulsion RT-PCR reaction, followed by nested PCR, sequencing and bioinformatic 
analysis. The entire process from B-cell isolation to the generation of VH:VL heat maps 
can be completed by a single investigator in 10 research hours over the course of four 
days (which includes three days for gene sequencing). For example, the work required to 
recover 2,716 unique VH:VL pairs from a sample of IgG+ peripheral B cells (Figure 2.2a) 
was completed by a single researcher in 10 h and cost $550. Analysis of 2,700 cells using 
established optimal single-cell RT-PCR protocols would have required >10 weeks of 
effort by an experienced technician and >$25,000 in reagent and sequencing costs11. 
Because only sequences of up to 500 bp can be accurately determined with 
current Illumina next-generation sequencing technology, our method detects the different 
antibody clonotypes (antibodies comprising the same CDR-H3:CDR-L3) but cannot yet 
distinguish somatic variants originating from clonally related B cells that contain 
upstream mutations between FR1 and CDR2 regions. However, this method 
distinguished nearly identical but distinct CDR3 regions, as indicated by B-cell clones 
2D02 and 3D05, which express light chain CDR3s that differ by only two nucleotides 
(Table A3.3). Rapid advances in next-generation sequencing read-length and quality will 
likely enable upstream somatic variant analysis in the near future. 
We used PCR amplification primers targeted to the FR1 region of heavy and light 
chains (primers reported in Tables A1.5–A1.7). In some chronic infections (e.g., HIV), 
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constant antigen exposure can generate antibodies that are highly mutated in all regions 
including the FR1 region, and therefore amplification with FR1-specific primers can bias 
the repertoire. In these cases, such bias can be readily circumvented by using primers that 
anneal to the leader peptide
94
.
Finally, we note that the analysis reported here focused on the light chain that was 
the dominant light chain paired with a particular VH. There are known, albeit rare, 
instances in mice where one heavy chain can be found paired with more than one light 
chain23. Bioinformatic analysis might discriminate between biologically relevant VH:VL 
pairs of one heavy chain with multiple light chains and false pairings that might result 
from multiple cells seeded into the same well of the experimental device; false pairings 
can be flagged because coincident cells 1 and 2 would yield the products VH1:VL2 and 
VH2:VL1 in addition to VH1:VL1 and VH2:VL2. 
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2.4 Methods 
2.4.1   PREPARATION OF MICROWELL SLIDES 
A grid of micropillars (56 µm diameter, 50 µm height) was photolithographically 
patterned onto a silica wafer using SU-8 photoresist (Fisher Scientific, Pittsburgh, PA) 
and the silica wafer was used as a mold to print polydimethylsiloxane (PDMS) slides 
(Sylgard 184, Dow Corning, Midland, MI) with the dimensions of a standard microscope 
slide and containing approximately 170,000 wells each.  
Molded PDMS slides were treated in an oxygen plasma chamber for 5 minutes to 
generate a hydrophilic surface.  The PDMS slides were blocked in 1% bovine serum 
albumin (BSA) for 30 minutes and washed with deionized water followed by phosphate-
buffered saline (PBS) to prepare for cell seeding.  
2.4.2 ANALYSIS OF MEMORY B-CELL VH:VL PAIRINGS IN RESPONSE TO SEASONAL
INFLUENZA VACCINATION
The study was approved by the University of Chicago Institutional Review Board 
(IRB# 09-043-A) and the University of Texas Institutional Review Board (IRB# 2012-
07-0002).  A healthy 30-year-old male was vaccinated with the 2010-2011 trivalent 
FluVirin influenza vaccine (Novartis) and blood was drawn at Day 14 after vaccination 
after informed consent had been obtained.  PBMCs were isolated and resuspended in 
DMSO/10%FCS for cryopreservation.  
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Frozen PBMCs were subsequently thawed and cell suspensions were stained in 
PBS/0.2% BSA with anti-human CD19 (HIB19, BioLegend, San Diego, CA), CD27 
(O323, BioLegend), CD38 (HIT2, BioLegend), and CD3 (7D6, Invitrogen, Grand Island, 
NY).  CD19
+
 CD3
-
 CD27
+
 CD38
int
 memory B cells were sorted using a FACSAria II
sorter system (BD Biosciences, San Diego, CA).  Cells were either cryopreserved in 
DMSO/10%FCS for subsequent high-throughput VH:VL pairing or single-cell sorted 
into 96-well plates containing RNAse Inhibitor Cocktail (Promega, Madison, WI) and 
10mM Tris-HCl pH 8.0 for single cell PCR analysis.  cDNA was synthesized from 
single-sorted cells using the Maxima First Strand cDNA Synthesis Kit (Fermentas, 
Waltham, MA) followed by amplification of the immunoglobulin variable genes using 
primer sets and PCR conditions previously described
76
.  Variable genes were determined
with in-house analysis software using the IMGT search engine
95
.
Memory B cells frozen for high-throughput VH:VL pairing were thawed and 
recovered by centrifugation at 250xg for 10 minutes.  Cells were resuspended in 200 uL 
RPMI-1640 supplemented with 1x GlutaMAX, 1x non-essential amino acids, 1x sodium 
pyruvate and 1x penicillin/streptomycin (Life Technologies) and incubated at 37°C for 13 
hours in a 96-well plate.  Recovered cells were centrifuged again at 250xg for 10 minutes 
and resuspended in 400 uL PBS, and 6 uL were withdrawn for cell counting with a 
hemocytometer.  Approximately 8,800 cells were recovered from frozen stock.  Memory 
B cells were then spiked with approximately 880 IM-9 cells (ATCC number CCL-159) as 
an internal control.  Cells were resuspended over two PDMS microwell slides (340,000 
wells) and allowed to settle into wells by gravity over the course of 5 minutes with gentle 
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agitation.  The cell seeding process has been calculated to be 90% efficient by measuring 
cell concentration in seeding buffers both pre- and post- cell seeding; thus 8,000 primary 
cells were analyzed in this experiment.  The fraction of cells isolated in the single and 
multiple cell per well states was calculated using Poisson statistics: 
𝑃(𝑘, 𝜇) =
𝜇𝑘𝑒−𝜇
𝑘!
where k equals the number of cells in a single microwell and μ is the average 
number of cells per well, so that the 1:39 cell:well ratio used in this experiment 
corresponds to 98.7% of cells deposited at an occupancy of one cell/well. 25 uL of 
poly(dT) magnetic beads (Invitrogen mRNA Direct Kit) were resuspended in 50 uL PBS 
and distributed over each PDMS slide surface, (mean of 55 poly(dT) beads per well).  
Magnetic beads were allowed to settle into wells by gravity for approximately 5 minutes, 
then a BSA-blocked dialysis membrane (12,000-14,000 MWCO regenerated cellulose, 25 
mm flat width, Fisher Scientific) that had been rinsed in PBS was laid over each slide 
surface, sealing the microwells and trapped cells and beads inside.  Excess PBS was 
removed from the slide and membrane surfaces using a 200 µL pipette.  500 µL of cell 
lysis solution (500 mM LiCl in 100 mM tris buffer (pH 7.5) with 1% lithium dodecyl 
sulfate, 10 mM EDTA, and 5 mM DTT) was applied to the dialysis membranes for 20 
min at room temperature.  Time-lapse microscopy revealed that all cells are fully lysed 
within 1 minute. Subsequently the slides were incubated at 4°C for 10 min at which point 
a Dynal MPC-S magnet was placed underneath the PDMS microwell device to hold 
magnetic beads inside the microwells as the dialysis membrane was removed with 
forceps and discarded.  Working quickly, the PDMS slides were sequentially inverted in 
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a Petri dish containing 2 mL of cold lysis solution and the magnet was applied 
underneath the Petri dish to force the beads out of the microwells.  Subsequently 1 ml 
aliquots of the lysis solution containing resuspended beads were placed into Eppendorf 
tubes and beads were pelleted on a Dynal MPC-S magnetic rack and washed once 
without resuspension using 1 mL per tube of wash Buffer 1 (100 mM Tris, pH 7.5, 500 
mM LiCl, 1 mM EDTA, 4°C). Beads were resuspended in wash Buffer 1, pelleted and 
resuspended in Wash Buffer 2 (20 mM Tris, pH 7.5, 50 mM KCl, 3 mM MgCl) and 
pelleted again.  Finally beads were suspended in 2.85 mL cold RT-PCR mixture (Quanta 
OneStep Fast, VWR) containing 0.05 wt% BSA (Invitrogen Ultrapure BSA, 50 mg/mL) 
and primer sets for VH and VL linkage amplification (Figure A1.1, Table A1.5)
52,96
.
The suspension containing the poly(dT) magnetic beads was added dropwise to a stirring 
IKA dispersing tube (DT-20, VWR) containing 9 mL chilled oil phase (molecular 
biology grade mineral oil with 4.5% Span-80, 0.4% Tween 80, 0.05% Triton X-100, 
v/v%, Sigma Aldrich, St. Louis, MO), and the mixture was agitated for 5 minutes at low 
speed.  The resulting emulsion was added to 96-well PCR plates with 100 µL emulsion 
per well and placed in a thermocycler.  The RT step was performed under the following 
conditions: 30 minutes at 55°C, followed by 2 min at 94°C.  PCR amplification was 
performed under the following conditions: four cycles of 94°C for 30 s denature, 50°C 
for 30 s anneal, 72°C for 2 min extend; four cycles of 94°C for 30 s denature, 55°C for 30 
s anneal, 72°C for 2 min extend; 22 cycles of 94°C for 30 s denature, 60°C for 30 s 
anneal, 72°C for 2 min extend; then a final extension step for 7 min at 72°C.  After 
thermal cycling the emulsion was visually inspected to ensure the absence of a bulk water 
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phase, which is a key indicator of emulsion stability.  Following visual verification, the 
emulsion was collected and centrifuged at room temperature for 10 minutes at 16,000xg, 
the mineral oil upper phase was discarded, and 1.5 mL diethyl ether was added to extract 
the remaining oil phase and break the emulsion.  The upper ether layer was discarded, 
two more ether extractions were performed and residual ether was removed in a 
SpeedVac for 25 minutes at room temperature.  The aqueous phase was diluted 5:1 in 
DNA binding buffer and passed through a silica spin column (DNA Clean & 
Concentrator, Zymo Research, Irvine, CA) to capture the cDNA product.  The column 
was washed twice with 300 µL wash buffer (Zymo Research Corp) and cDNA was eluted 
into 40 µL nuclease-free water.  Finally a nested PCR amplification was performed 
(ThermoPol PCR buffer with Taq Polymerase, New England Biosciences, Ipswich, MA) 
in a total volume of 200 µL using 4 µL of eluted cDNA as template with 400 nM primers 
(Table A1.6) under the following conditions:  2 min initial denaturation at 94°C, 
denaturation at 94°C for 30 s for 39 cycles, annealing at 62°C for 30 s and extension at 
72°C for 20 s, final extension at 72°C for 7 min. The approximately 850 bp linked 
product was extracted by agarose gel electrophoresis and sequenced using the 2x250 
paired end MiSeq NextGen platform (Illumina, San Diego, CA). 
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2.4.3 ANALYSIS OF PLASMABLAST VH:VL PAIRINGS IN RESPONSE TO TETANUS TOXOID
VACCINATION
One female donor underwent booster immunization against tetanus toxoid 
(TT)/diphteria toxoid (TD, 20 I.E. TT and 2 I.E. diphteria toxoid, Sanofi Pasteur Merck 
Sharpe & Dohme GmbH, Leimen, Germany) after informed consent by the Charité 
Universiätsmedizin Berlin had been obtained (samples were anonymously coded and 
study approved by the hospital's ethical approval board, number EA1/178/11, and the 
University of Texas at Austin Institutional Review Board, IRB# 2011-11-0095).  At 7 
days post tetanus toxoid immunization, EDTA blood was withdrawn and PBMC isolated 
by density gradient separation as described
97
.  PBMCs were stained in PBS/BSA at 4°C
for 15 min with anti-human CD3/CD14-PacB (clones UCHT1 and M5E2, respectively, 
Becton-Dickinson, BD), CD19-PECy7 (clone SJ25C1, BD), CD27-Cy5 (clone 2E4, kind 
gift from René van Lier, Academic Medical Centre, University of Amsterdam, The 
Netherlands, labelled at the Deutsches Rheumaforschungszentrum (DRFZ), Berlin), 
CD20-PacO (clone HI47, Invitrogen), IgD-PerCpCy5.5 (clone L27, BD), CD38-PE 
(clone HIT2, BD), and TT-Digoxigenin (labeled at the DRFZ) for 15 minutes at 4°C.  
Cells were washed and a second staining was performed with anti-Digoxigenin-FITC 
(Roche, labeled at the DRFZ) and DAPI was added prior to sorting.  CD19
+
CD3
-
CD14
-
CD38
++
CD27
++
CD20
-
TT
+
 plasmablasts were sorted using a FACSAria II sorter system
(BD Biosciences).  A portion of sorted cells were washed and cryopreserved in 
DMSO/10%FCS for high-throughput VH:VL pairing. 
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One vial containing approximately 2,000 frozen TT
+
 plasmablasts was thawed
and recovered by centrifugation at 250xg for 10 minutes, for which 20-30% recovery was 
anticipated
21
.  Cells were resuspended in 300 L RPMI-1640 supplemented with 10%
FBS, 1x GlutaMAX, 1x non-essential amino acids, 1x sodium pyruvate and 1x 
penicillin/streptomycin (all from Life Technologies) and incubated at 37°C for 13 hours 
in a 96-well plate.  Recovered cells were centrifuged again at 250xg for 10 minutes and 
resuspended in 400 L PBS, and 6 L were withdrawn for cell counting with a 
hemocytometer.  Cells were spiked with approximately 30 ARH-77 cells as an internal 
control (ATCC number CRL-1621) and VH:VL transcripts were linked as described 
above, omitting IgM primers and using a 38-cycle nested PCR; the resulting product was 
submitted for 2x250 MiSeq sequencing.  VH and VL chains were also amplified 
individually to obtain full VH and VL sequences for antibody expression.  Nested PCR 
product was diluted 1:9 and 0.5 L were used as template in a PCR reaction with the 
following conditions:  400 nM primers (Table A1.7), 2 min initial denaturation at 94°C, 
denaturation at 94°C for 30 s for 12 cycles, annealing at 62°C for 30 s and extension at 
72°C for 15 s, final extension at 72°C for 7 min.  The resulting ~450 bp VH or ~400 bp 
VL products were purified by agarose gel electrophoresis and submitted for 2x250 MiSeq 
sequencing. 
Ten VH and VL pairs were selected from TT
+
 plasmablast pairings and cloned
into the human IgG expression vectors pMAZ-VH and pMAZ-VL respectively
98
.  40 μg
each of circularized ligation product were co-transfected into HEK 293F cells 
(Invitrogen, NY, USA). Medium was harvested 6 days after transfection by 
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centrifugation and IgG was purified by a protein-A agarose (Pierce, IL, USA) 
chromatography column. 
Antigen affinities were determined by competitive ELISA
99
 using different
concentrations of IgG in a serial dilution of antigen, ranging from 100 nM to 0.05 nM in 
the presence of 1% milk in PBS.  Plates were coated overnight at 4°C with 10 µg/mL of 
TT in 50 mM carbonate buffer, pH 9.6, washed three times in PBST (PBS with 0.1% 
Tween 20), and blocked with 2% milk in PBS for two hours at room temperature.  Pre-
equilibrated samples of IgG with TT antigen were added to the blocked ELISA plate, 
incubated for one hour at room temperature, and plates were washed 3x with PBST and 
incubated with 50 µl of anti-human kappa light chain-HRP secondary antibody (1:5,000, 
2% milk in PBS) for ~2 min, 25°C.  Plates were washed 3x with PBST, then 50 µl Ultra 
TMB substrate (Thermo Scientific, Rockford, IL) was added to each well and incubated 
at 25°C for 5 min. Reactions were stopped using equal volume of 1M H2SO4 and 
absorbance was read at 450 nm (BioTek, Winooski, VT).  Each competitive ELISA 
replicate was fit using a four-parameter logistic (4PL) equation, with error represented as 
the standard deviation of 2-3 replicates for each IgG analyzed. 
2.4.4 ANALYSIS OF IGG
+
 CLASS SWITCHED CELLS IN HEALTHY DONOR PERIPHERAL
BLOOD
PBMC from two different anonymous healthy donors (Texas Gulf Coast Regional 
Blood Center) were isolated from whole blood using Histopaque-1077 centrifugation 
gradient (Sigma-Aldrich) according to manufacturer protocols.  3.8x10
8
  PBMCs were
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used as input for cell purification using a IgG
+
 Memory B Cell Isolation Kit (Miltenyi
Biotec, Auburn, CA)  Approximately 68,000 cells (Fig. 2a) or 52,000 (Fig. A1.2) cells 
were spiked with 4% IM-9 immortalized B lymphoblast cells (ATCC number CCL-159) 
and seeded onto four or three PMS microwell slides, respectively, at a 1:10 cell:well ratio 
corresponding to 95.1% of cells isolated as single cells by Poisson distribution.  Cell 
seeding was calculated to be 90% efficient and thus 61,000 cells (Figure 2.1a, Table 
A1.1) or 47,000 cells (Fig. A1.2, Table A1.2) were analyzed.  VH:VL chains were paired 
and amplified as above using 35 nested PCR cycles and sequenced on the Illumina MiSeq 
platform.. 
2.4.5 BIOINFORMATIC  METHODS
Raw 2x250 MiSeq data were filtered for minimum Phred quality score of 20 over 
50% of nucleotides to ensure high read quality in the CDR3-containing region 
(approximately HC nt 65-115 or LC bases 55-100).  Sequence data were submitted to the 
International ImMunoGeneTics Information System (IMGT) for mapping to germline 
V(D)J genes
95
.  Sequence data were filtered for in-frame V(D)J junctions and productive
VH and V/λ sequences were paired by Illumina read ID.  CDR-H3 nucleotide sequences 
were extracted and clustered to 96% nt identity with terminal gaps ignored, to generate a 
list of unique CDR-H3s in the data set.  96% nt identity cutoff was found to be the 
optimal cutoff to cluster sequencing error in spiked control clones; the number of unique 
CDR-H3 sequences and hence the number of unique V genes reported refer to the 
number of clusters recovered from the sample (Table A1.1, Table A1.2).  
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Overwhelmingly the frequency of the top VL pair for a given VH was observed to be 
greater than 90%, and the top VL pair for each CDR-H3 was used for comparison with 
single cell RT-PCR for workflow validation (Table A1.3), consensus sequence generation 
and paired VH:VL expression (Table 2.1), and VH:VL gene family heat maps (Figure 
2.2, Figure A1.2, Figure A1.3).  In the case of separate VH and VL gene amplification for 
complete antibody sequencing, 2x250bp reads containing the 5’ V gene FR1-CDR2 and 
3’ CDR2-FR4 were paired by Illumina read ID and consensus sequences were 
constructed from reads containing the exact CDR3 of interest.  Sequence data was 
deposited in the NCBI Short Read Archive (SRA061316). 
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3. IN-DEPTH DETERMINATION AND ANALYSIS OF THE HUMAN
PAIRED HEAVY AND LIGHT CHAIN ANTIBODY REPERTOIRE2
3.1 Introduction 
The determination of immune receptor repertoires using high throughput 
(NextGen) DNA sequencing is rapidly becoming an indispensable tool for the 
understanding of adaptive immunity, antibody discovery and in clinical practice
2,29,100
.
However, because the variable domains of antibody heavy and light chains (VH and VL, 
respectively) are encoded by different mRNA transcripts, until recently it was only 
possible to determine the VH and VL repertoires separately, or else paired VH:VL 
sequences for small numbers, and more recently, moderate numbers of cells (10
4–105)82,
far smaller than the ~0.7–4x106 B cells contained in a typical 10 ml blood draw. Thus a
technology for the facile determination of the paired antibody VH:VL repertoire at great 
depth (i.e. >10
6
 cells per analysis) and for a variety of B cell subsets is still needed for
clinical research
101
, antibody discovery
76,79
, and for addressing a host of important
questions related to the shaping of the antibody repertoire
2,5–7,102–104
.
2 DeKosky, B. J. et al. In-depth determination and analysis of the human paired heavy- and light-chain 
antibody repertoire. Nat. Med. 21, 89-91 (2014).  B.J.D. and G.G. developed the methodology and 
wrote the manuscript; B.J.D., T.K., G.C.I., A.D.E. and G.G. designed the experiments; B.J.D., T.K., 
A.R. and W.C. performed the experiments; B.J.D. carried out the bioinformatic analysis; and B.J.D. and 
T.K. analyzed the data. 
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Several techniques have been reported for detection or sequencing of genomic 
DNA or cDNA from single cells; however all are limited by low efficiency or low cell 
throughput (< 200–500 cells) and require fabrication and operation of complicated 
microfluidic devices
70,72–74
.  Chudakov and coworkers recently reported the use of one-
pot cell encapsulation within water-in-oil emulsions, cell lysis by heating at 65°C 
concomitant with TCR  and  reverse transcription and finally, linking by overlap 
extension PCR to determine TCR:TCR pairings, albeit only for TCRV and with a 
very low efficiency (approximately 700 TCR:TCR pairs recovered from 8x106
PBMC)
74
.   This is likely because one-pot emulsions result in a high degree of droplet
size dispersity and since the RT reaction is inhibited in volumes <5 nL
72
 only the small
fraction of cells encapsulated within larger droplets yields cDNA for further 
manipulation.  
Inspired by methods for the production of highly monodisperse polymeric 
microspheres for drug delivery purposes
105,106
, we developed a new technology that
enables sequencing of the paired VH:VL repertoire from millions of B cells within a few 
hours of experimental effort and using equipment that can be built inexpensively by any 
laboratory.   For validation we expanded in vitro memory B cells isolated from human 
PBMCs to obtain a sample that contained multiple clones of individual B cells and 
showed that among aliquots (technical replicates) the accuracy of VH:VL pairing is 
>97%.  We show that ultra-high throughput determination of the paired VH:VL 
repertoire provides important immunological insights such as: (i) the discovery of human 
light chains detected in multiple individuals that pair with a wide range of VH genes, (ii) 
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the quantitative analysis of allelic inclusion in humans, i.e. of B cells expressing two 
different antibodies, and (iii) estimates of the frequencies of antibodies in healthy human 
repertoires that display known features of broadly neutralizing antibodies to rapidly 
evolving pathogens.  
3.2 Results 
3.2.1 DEVICE CONSTRUCTION 
For facile high-throughput single-cell manipulation we assembled a simple 
axisymmetric flow-focusing device comprising three concentric tubes: an inner needle 
carrying cells suspended in PBS, a middle tube carrying a lysis solution and magnetic 
poly(dT) beads for mRNA capture from lysed cells, and finally an external tube with a 
rapidly flowing annular oil phase, all of which passed through a 140 m glass nozzle 
(Figure 3.1a).  The rapidly flowing outer annular oil phase focused the slower-moving 
aqueous phase into a thin, unstable jet that coalesced into droplets with a predictable size 
distribution; additionally maintaining laminar flow regime within the apparatus prevented 
mixing of cells and lysis solution prior to droplet formation (Figure A2.1). 
To evaluate cell encapsulation and droplet size distribution, MOPC-21 
immortalized B cells suspended in PBS were injected through the inner needle at a rate of 
250,000 cells/min while a solution of PBS containing the cell viability dye Trypan blue 
(0.4% v/v) was injected through the middle tubing so that dye mixed with cells at the 
point of droplet formation.  Resulting emulsion droplets were 73±20 µm in diameter 
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(average±SD).  Trypan blue exclusion revealed that, as expected, cells remained viable 
throughout the emulsification process (Figure A2.2).  Replacing the Trypan blue stream 
with cell lysis buffer containing lithium dodecyl sulfate (LiDS) and DTT to inactivate 
RNases resulted in complete cell lysis as indicated by visual disappearance of cell 
membranes from emulsion droplets. 
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Figure 3.1 Technical workflow for ultra-high throughput VH:VL sequencing from single 
B cells.  (a) An axisymmetric flow-focusing nozzle isolated single cells and poly(dT) 
magnetic beads into emulsions of predictable size distributions.  An aqueous solution of 
cells in PBS (center, blue/pink circles) and cell lysis buffer with poly(dT) beads 
(gray/orange circles) exited an inner and outer needle and were surrounded by a rapidly 
moving annular oil phase (orange arrows).  Aqueous streams focused into a thin jet which 
coalesced into emulsion droplets of predictable sizes, and cells mixed with lysis buffer 
only at the point of droplet formation (Fig. A2.1).  (b) Single cell VH and VL mRNAs 
annealed to poly(dT) beads within emulsion droplets (blue figure represents a lysed cell, 
orange circles depict magnetic beads, black lines depict mRNA strands).  (c) poly(dT) 
beads with annealed mRNA were recovered by emulsion centrifugation to concentrate 
aqueous phase (left) followed by diethyl ether destabilization (right).  (d) Recovered 
beads were emulsified for cDNA synthesis and linkage PCR to generate an ~850–base 
pair VH:VL cDNA product.  (e) Next-generation sequencing of VH:VL amplicons was 
used to analyze the native heavy and light chain repertoire of input B cells. 
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3.2.2 SINGLE B CELL VH:VL PAIRING: THROUGHPUT AND PAIRING ACCURACY 
Human CD3
-
CD19
+
CD20
+
CD27
+
 memory B cells were isolated from PBMCs
from a healthy volunteer and expanded for four days in vitro by stimulation with anti-
CD40 antibody, IL-4, IL-10, IL-21, and CpG oligodeoxynucleotides
107
.   In vitro
expansion was performed to create a cell population containing a sufficient number of 
clonal B cells so that the concordance of the VH:VL repertoire in two technical replicates 
could be assessed.  1,600,000 in vitro expanded B cells were divided into two aliquots 
and passed through the flow-focusing nozzle at a rate of 50,000 cells/min (i.e. 16 minutes 
emulsification for each replicate) and processed as shown in Figure 3.1.  The emulsion of 
lysed single cells with compartmentalized poly(dT) beads was maintained for three 
minutes at room temperature to allow specific mRNA hybridization onto poly(dT) 
magnetic beads (Figure 3.1b), then the emulsion was broken chemically (Figure 3.1c), 
beads were re-emulsified, and overlap extension RT-PCR was performed to generate 
linked VH:VL amplicons (Figure 3.1d).  The resulting cDNAs were amplified by nested 
PCR to generate an ~850 bp VH:VL product for NextGen sequencing by Illumina MiSeq 
2x250 or 2x300.  Due to read length limitations of current NextGen sequencing 
technologies, the FRH4-(CDR-H3)-FRH3:FRL3-(CDR-L3)-FRL4 was sequenced first to 
reveal the pairing of the VH and VL hypervariable loops.  Each of these VH:VL pairs 
may also comprise one or more somatic variants containing mutations within the 
upstream portion of the VH and VL genes.   We determine the complete set of somatic 
variants by separate MiSeq sequencing the VH and VL portions of the paired 850 bp 
VH:VL amplicon followed by in silico gene assembly
82
.
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Sequence data were processed by read quality filtering, CDR-H3 clustering, 
VH:VL pairing, and selection for paired VH:VLs with 2 reads in the dataset.  The 
clustering step resulted in high-confidence sequence data but with a lower-bound 
estimate of clonal diversity because clonally expanded or somatically mutated B cells 
with similar VH sequences collapse into a single CDR-H3 cluster.  129,097 VH:VL 
clusters were observed after separate analysis and clustering of Replicates 1 and 2. Of 
these, 37,995 CDR-H3 sequences were observed in both replicates (and hence must have 
originated from expanded B cells present in both technical replicates) with 36,468 paired 
with the same CDR-L3 across replicates revealing a VH:VL pairing precision of 98.0% 
(Figure 3.2, Table 3.1, Figure A2.3, see Methods).  The ratio of VH:VL clusters to input 
cells observed (typically between 1:10 to 1:15) is a reflection of the clonality of the 
memory B cell population (i.e. presence of clonally related memory B cells), clustering 
threshold, RT-PCR efficiency and cell viability.  For comparison, in our hands, 
sequencing the memory B cell VH repertoire by preparing amplicons directly by standard 
RT-PCR without pairing and using the same bioinformatic filters (sequences present at 
2 reads, 96% clustering) resulted in a 1:6 ratio of VH clusters:input cells, which 
compares favorably to the yield of paired VH:VL clusters in Table 3.1.  Two additional 
pairing analyses of somewhat smaller B cell populations from different donors were also 
performed (Table 3.1, Figures A2.4 and A2.5).  In a separate experiment designed to 
verify native VH:VL pairing accuracy, plasmids encoding 11 different known human 
antibodies were transfected separately into HEK293 cells. Aliquots containing 
comparable numbers of each of the transfected cells were mixed and processed as 
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described in Figure 3.1, and native pairings were identified for 11/11 antibodies (Table 
A2.1).  In yet another test, approximately 260 ARH-77 immortalized human B cells
4
were mixed with 20,000 CD3
-
CD19
+
CD20
+
CD27
+
 expanded memory B cells (~100-fold
excess).  ARH-77 heavy and light chains were paired correctly and the ratio of correctly 
paired ARH-77 VH:VL reads over the top correctVH:incorrectVL, a parameter that we 
denote signal:topVLnoise, was 96.4:1 (2,604 correct ARH-77 VH:VL reads vs. 27 reads 
for the top ARH-77 VH paired with an incorrect VL, Table A2.2). 
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Figure 3.2 Heavy:light V-gene pairing landscape of CD3
-
CD19
+
CD20
+
CD27
+
 peripheral memory B cells in two healthy human
donors.  V genes are plotted in alphanumeric order; height indicates percentage representation among VH:VL 
clusters.  (a) Donor 1 (n = 129,097), (b) Donor 2 (n = 53,679).  VH:VL gene usage was highly correlated between 
Donors 1 and 2 (Spearman rank correlation coefficient 0.757, p < 1x10
–99
).  Additional heat maps are provided in Figures
A2.3 and A2.4. 
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Human 
donor 
V-region 
primer set 
# cells 
analyzed 
Emulsification 
rate (cells/min) 
Observed 
VH:VL clusters 
CDR-H3 
detected in both 
replicates 
CDR-H3:CDR-L3 
clusters detected in 
both replicates 
VH:VL pairing 
precision 
Donor 1 Framework 1 1,600,000 50,000 129,097 37,995 36,468 98.0% 
Donor 2 Framework 1 810,000 50,000 53,679 19,096 18,115 97.4% 
Donor 3 Leader peptide 210,000 33,000 15,372 4,267 4,170 98.9% 
Table 3.1 High-throughput VH:VL sequence analysis of CD3
-
CD19
+
CD20
+
CD27
+
 in vitro-expanded human B cells.
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As discussed above, three sequencing reactions and in silico assembly are needed 
to determine the sequence of the complete linked VH:VL amplicon with Illumina MiSeq 
2x250 or 2x300.  Alternatively, the long-read Pacific Biosciences (PacBio) sequencing 
platform can be used to obtain the complete ~850bp cDNA encoding linked VH:VL 
sequences.  However, because of its substantially lower throughput and higher cost per 
read, we find that despite the need for three distinct MiSeq samples compared to only one 
for PacBio, the former is currently much more cost-effective for deep repertoire analyses.  
We found PacBio sequencing to be preferable only for certain specialized applications, 
for example in identifying VH:VL pairs in antibodies with extensive SHM such as 
broadly neutralizing antibodies that arise following persistent infection with rapidly 
evolving viruses, most notably HIV-1.  For example, we used PacBio to sequence 15,000 
VH:VL amplicons from elite controller CAP256
79
 and identified six variants of VRC26-
class HIV broadly neutralizing antibodies within the VH:VL repertoire (Figures A2.6 and 
A2.7). 
3.2.3 PROMISCUOUS & PUBLIC VL JUNCTIONS 
In contrast to the heavy chain, light chain rearrangements do not incorporate a 
diversity segment and exhibit restricted CDR-L3 lengths with low levels of N-addition.  
Light chains therefore have a much lower theoretical diversity than heavy chains and the 
presence of light chain sequences paired with multiple heavy chains within a single 
donor, referred to as “repeated” or “promiscuous” light chains, is an expected result, 
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especially for VL junctions that are mostly germline encoded and also derive from V- and 
J-genes with high prevalence in human immune repertoires
108
.  However the separate
high-throughput sequencing of VH and VL repertoires, as has been practiced until now, 
cannot provide VH pairing information for a given VL and thus precludes identification 
and characterization of promiscuous light chains
41,109
.  We observed thousands of heavy
chains paired with promiscuous VL nucleotide junctions (34.9%, 29.4% and 19.6% of all 
heavy chains were paired with promiscuous VL junctions in Donors 1, 2, and 3, 
respectively).  We inspected high-frequency promiscuous light chains to see if any 
promiscuous VL might be shared across individuals (i.e. a “public” VL).  We found that 
highly promiscuous VLs were nearly always public:  for example, of the 50 highest-
frequency promiscuous VL junctions in Donor 1, 49/50 were also detected in Donors 2 
and 3.  Promiscuous light chains showed an average of 0.04 non-templated bases in the 
VL junction compared to an average of 5 non-templated bases in non-promiscuous light 
chains (i.e. VLs that paired with a single VH in a donor, see Figure A2.8, p < 10
–10
).  The
lack of non-templated bases in promiscuous VL junctions indicated that promiscuity can 
be observed mainly in germline-encoded VL genes lacking SHM. 
We examined in detail two representative promiscuous and public VL junctions 
that contained V- and J-genes with high prevalence in steady-state human immune 
repertoires (KV1-39:KJ2, 9 aa CDR-L3, LV1-44:LJ3, 11 aa CDR-L3, both observed at a 
frequency of ~1 per 1,000 VH:VL clusters)
52,92
 to check for biases in VH pairing of
promiscuous VL chains.  KV1-39:KJ2 and LV1-44:LJ3 both paired with VH genes of 
diverse germline lineage and CDR-H3 length that reflected the overall VH gene usage in 
58 
the repertoire (Figure 3.3, Spearman rank correlation coefficients: KV1-39:KJ2 ρ = 0.889, 
p < 10
–21
; LV1-44:LJ3 ρ = 0.847, p < 10–17), indicating that VL nucleotide-sequence
promiscuity arises mostly from distinct VL recombination events rather than B cell 
activation and subsequent clonal expansion.  We note that no two donors shared more 
than 2 VH nucleotide sequences, and no VH sequence was detected in all three donors, 
consistent with previous reports which showed that in contrast to VL junctions, the VH 
nucleotide repertoire is highly private
2,92
.
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Figure 3.3 (a) VH gene family utilization in:  left total paired VH:VL repertoires (Donor 1 n = 129,097, Donor 2 n = 53,679, Donor 3 
n = 15,372), center heavy chains paired with a representative highly-ranked public and promiscuous VL observed in all 
three donors (KV1-39:KJ2 9 aa CDR-L3, tgtcaacagagttacagtaccccgtacactttt; Donor 1 n = 106, Donor 2 n = 41, Donor 3 n 
= 20),  right heavy chains paired with a different highly-ranked public VL in all three donors (LV1-44:LJ3 11 aa CDR-
L3, tgtgcagcatgggatgacagcctgaatggttgggtgttc; n = 76, n = 32 and n = 28, respectively).  (b) CDR-H3 length distribution in 
VH:VL repertoires (Donor 1 n = 129,097, Donor 2 n = 53,679, Donor 3 n = 15,372).  (c) CDR-H3 length distribution for 
all antibodies containing the two representative public VL chains from part (a).
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3.2.4 QUANTIFYING ALLELIC INCLUSION IN HUMAN MEMORY B CELLS 
Clonal selection theory postulates that each lymphocyte expresses one antibody.  
However, studies in mice have confirmed that this is not always the case.  Allelic 
inclusion, the phenomenon whereby one B cell expresses two BCRs, overwhelmingly 
one VH gene with two different VLs, has been well-documented in mice and has been 
proposed to be particularly important in autoimmunity because the expression of a second 
BCR can dilute a pre-existing auto-reactive BCR and limit the expansion of autoreactive 
B cells.  Similarly allelic inclusion can also provide a mechanism for autoreactive 
antibodies to evade central tolerance
110–114
.  Almost 20 years ago A. Lanzavecchia and 
coworkers used FACS sorting of cells expressing both  and  immunoglobulin proteins 
on their cell surface (sIg+/sIg+, denoting surface-expression of both Ig and Ig) 
followed by EBV immortalization to show that sIg+/sIg+ allelic inclusion occurs in 
0.2–0.5% of human memory B cells115.  However, the inability to sort dual sIg+ and 
dual sIg+ human B cells and the absence of methods for the determination of the VH:VL 
repertoire at sufficient depth (since the frequency of allelic inclusion is low) have 
precluded more comprehensive determination of allelic inclusion in humans.  We 
detected VL allelic inclusion at a rate of approximately 0.4% of VH clusters for Donor 1 
and Donor 2, with dual /-transcribing B cells in approximately equal proportions to 
dual /- and /-transcribing B-cell clones (Figure 3.4).  These heavy chains paired only 
with their two allelically included light chains (exact nucleotide match) in two technical 
replicates, and we observed that approximately 80% of these antibodies displayed 
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somatic mutations.  The somatic mutation frequency detected in allelically included 
VH:VL pairs was comparable to previous reports by Lanzavecchia et al. for allelically 
included sIg+/sIg+ cells (3/5 EBV-immortalized clones115).  Also consistent with the
earlier study, we observed stop codons resulting from somatic mutation that inactivated a 
subset of allelically included VL transcripts
115
.  For the ~20% of allelically included VH
that do not display SHM, we cannot rule out the possibility that these clones were derived 
from pre-B expansion.  
Figure 3.4  Frequency of VL transcript allelic inclusion in two donors (n = 184 and n = 
64 allelically included antibodies from n = 37,995 and n = 19,096 VH:VL 
clusters detected across replicates in Donor 1 and Donor 2, respectively).  14 
allelically included antibodies were detected in Donor 3 (8 dual /, 2 dual 
, 2 dual , n = 4,267 VH:VL clusters detected across replicates).  
Numbers above each category indicate the absolute number of observed 
allelically included antibodies. 
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3.2.5 ANTIBODIES WITH GENE SIGNATURES OF KNOWN ANTI-VIRAL BNABS 
High-resolution sequence descriptions of the immune repertoire can inform on B 
cell trajectories for the emergence of broadly neutralizing antibodies (bNAbs) to rapidly 
evolving pathogens
7,79,116,117
.  Many bNAbs display highly unusual features including
very long CDR-H3 and short CDR-L3 sequences
79,116,118,64
, and these properties have
raised the question as to whether antibodies with similar features are normally found in 
the repertoire of healthy donors and thus could evolve following stimulation by infection 
or vaccination to yield neutralizing antibodies.  We found approximately 1:6,000 VH:VL 
clusters exhibited general characteristics of known VRC01-class anti-HIV antibodies (22, 
9, and 0 for Donors 1, 2, and 3 respectively; germline VH1-02, a very short 5aa CDR-
L3, and CDR-H3 length between 11 and 18 aa
64
), while antibodies with genetic
characteristics of anti-influenza FI6 occurred in approximately 2–5x104 memory B cells
(6 and 1 antibodies detected in Donors 1 and 2, respectively; VH3-30, KV4-1, 22aa CDR-
H3, 9aa CDR-L3
116
).
3.3 Discussion 
We have developed an easy to implement, ultra high-throughput technology for 
sequencing the VH:VL repertoire at relatively low cost and with high pairing accuracy.  
The workflow presented here permits sequence analysis of the entire population of 
human B cells contained in a 10 mL blood draw, or if needed, even in a unit of blood 
(450 ml) in a single-day experiment, an improvement orders of magnitude relative to 
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what is feasible using robotic single-cell RT-PCR
119
.  As many as 6 million B cells (or 
alternatively, as few as 1,000 B cells) can be analyzed per operator in a single day.  Of 
note, the number of antibody sequences reported here (~200,000) dwarfs the entire set of 
<19,000 human VH:VL sequences that had been deposited in the International 
Nucleotide Sequence Database Collaboration (INSDC) over the past 25 years (in addition 
to the ~5,000 human VH:VL pairs we reported previously
82
).  
The determination of the paired antibody repertoire at great depth can provide 
unprecedented insights on a number of medically and immunologically important issues.  
For example, we used HT single-cell VH:VL sequencing to detect highly-utilized 
promiscuous and germline-encoded VL junctions that are observed in multiple donors, to 
identify antibodies with bNAb-like features in HIV-1 patients
79
 (Figures A2.6 and A2.7) 
and to quantify the frequency of bNAb-like V gene rearrangements in healthy donors, as 
described above.  The latter is an important factor in determining whether a vaccine 
immunogen might be able to elicit protective immunity
64,118
.  High-throughput VH:VL 
sequencing can also be used to search for public antibody VH:VL clonotypes
120,121
 and to 
identify antibodies having specific features determined by computational or structural 
biology analyses or with relevance to pathogen neutralization
35,65,66,79,64
.  In 
autoimmunity, high-throughput VH:VL sequencing can reveal an individual’s repertoire 
of allelically included B cells (Figure 3.4) and the presence of B cell clones expressing 
antibodies containing hallmark autoimmune signatures (with respect to paratope net 
charge, CDR-H3 and CDR-L3 lengths, etc.) as well as other attributes of potential 
diagnostic and therapeutic utility
111,113,114
.  
64 
3.4 Methods 
3.4.1 FLOW FOCUSING APPARATUS:
An axisymmetric flow focusing emulsification apparatus was constructed by 
inserting a 26-gauge needle within 19-gauge hypodermic tubing (Hamilton Company, 
Reno, NV, USA) and the needle was adjusted so that the needle tip was nearly flush with 
the end of the hypodermic tubing (Fig. A2.1). The concentric needles were placed inside 
3/8 inch OD glass tubing (Wale Apparatus, Hellertown, PA, USA) with a 140 μm orifice 
such that the needle exit was approximately 2 mm from the nozzle orifice.  A syringe 
pump (KD Scientific Legato 200, Holliston, MA, USA) was used to control aqueous flow 
rates and a gear pump (M-50, Valco Instruments, Houston, TX, USA) was used to control 
oil flow rates.  The flow focusing nozzle and supply lines were cleaned using 70% EtOH 
followed by PBS prior to all experiments. 
3.4.2 SINGLE-CELL EMULSIFICATION, CELL VIABILITY AND LYSIS ANALYSES 
MOPC-21 cells were resuspended at a concentration of 500,000 cells/mL in PBS 
and the resulting cell solution was injected through the needle at 500 µL/min.  A 
PBS/0.4% Trypan blue solution (Sigma-Aldrich, St. Louis, MO, USA) was injected 
through the 19 ga hypodermic tubing at 500 µL/min and oil phase (molecular biology 
grade mineral oil with 4.5% Span-80, 0.4% Tween 80, 0.05% Triton X-100, v/v%, Sigma 
Aldrich Corp.) passed through the glass tubing at 3 mL/min.  The resulting emulsion was 
analyzed via light microscopy (Figure A2.2); ImageJ post-processing was used to 
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measure droplet diameters.  Next the PBS/0.4% Trypan blue solution was replaced a 
solution of poly(dT) magnetic beads (1.0 µm diameter, New England Biosciences, 
Ipswich, MA, USA) pelleted and resuspended in cell lysis/binding buffer (100 mM Tris 
pH 7.5, 500 mM LiCl, 10 mM EDTA, 1% lithium dodecyl sulfate, 5 mM DTT) at a 
concentration of 45 uL magnetic bead stock/mL lysis/binding buffer to verify cell lysis.  
Upon emulsification no cell membranes could be observed, indicating total cell lysis 
(data not shown).  
3.4.3 VH:VL PAIRING OF TECHNICAL REPLICATES OF EXPANDED MEMORY B CELLS 
PBMC were isolated from donated human whole blood after informed consent 
had been obtained (Gulf Coast Regional Blood Center, Houston, TX) and non-B cells 
were depleted via magnetic bead sorting (Miltenyi Biotec, Auburn, CA).  B cells were 
stained with anti-CD20-FITC (clone 2H7, BD Biosciences, Franklin Lakes, NJ, USA), 
anti-CD3-PerCP (HIT3a, BioLegend, San Diego, CA, USA), anti-CD19-v450 (HIB19, 
BD), and anti-CD27-APC (M-T271, BD). CD3
-
CD19
+
CD20
+
CD27
+
 memory B cells
were incubated four days in the presence of RPMI-1640 supplemented with 10% FBS, 1× 
GlutaMAX, 1× non-essential amino acids, 1× sodium pyruvate and 1× 
penicillin/streptomycin (Life Technologies) along with 10 µg/mL anti-CD40 antibody 
(5C3, BioLegend), 1 µg/mL CpG ODN 2006 (Invivogen, San Diego, CA, USA), 100 
units/mL IL-4, 100 units/mL IL-10, and 50 ng/mL IL-21
107
 (PeproTech, Rocky Hill, NJ,
USA, Table A2.3).  Memory B cells were then resuspended in PBS at a concentration of 
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100k/mL and passed through the innermost, 26-gauge needle of the flow focusing device 
at 500 µL/min.  poly(dT) magnetic beads (1.0 µm diameter, New England Biosciences, 
Ipswich, MA, USA) were pelleted and resuspended in cell lysis/binding buffer (100 mM 
Tris pH 7.5, 500 mM LiCl, 10 mM EDTA, 1% lithium dodecyl sulfate, 5 mM DTT) at a 
concentration of 45 μL magnetic bead stock/mL lysis/binding buffer.  The cell lysis/beads 
mixture was passed through the 19-gauge hypodermic tubing at 500 µL/min while oil 
phase (molecular biology grade mineral oil with 4.5% Span-80, 0.4% Tween 80, 0.05% 
Triton X-100, v/v%, Sigma Aldrich Corp.) was passed through the outermost glass tubing 
at 3 mL/min.  The emulsified stream was collected into a series of 2 mL Eppendorf tubes, 
and each tube was maintained at room temperature for three minutes before being placed 
on ice for a minimum of twenty minutes.  Tubes were centrifuged at 16,000 x g for 5 
minutes at 4°C, and the upper mineral oil layer was discarded.  200 µL cold water-
saturated diethyl ether was added to break the emulsion in each tube and the tubes were 
centrifuged again at 16,000 x g for 5 minutes at 4°C to pellet the beads; for larger 
emulsion volumes (Donor 1) emulsion collected in Eppendorf tubes was pooled into a 50 
mL conical for centrifugation at 5,000 rpm for 7 min at 4°C, and the emulsion was 
broken with an equal volume of cold diethyl ether after removal of the upper mineral oil 
layer.  Magnetic beads were withdrawn using a pipette, pelleted, washed once in cold 
wash buffer (100 mM Tris pH 7.5, 500 mM LiCl, 1 mM EDTA) and then resuspended in 
2 mL cold lysis/binding buffer (100 mM Tris pH 7.5, 500 mM LiCl, 10 mM EDTA, 1% 
LiDS, 5 mM DTT).  Beads were washed and resuspended in OE RT-PCR mixture as in 
previous reports
82
.  The OE RT-PCR mixture bead suspension was emulsified and
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thermally cycled, cDNA was extracted, and a nested PCR was performed as reported 
previously.  Nested PCR product was electrophoresed to purify ~850 bp linked 
transcripts and sequenced via Illumina 2 x 250 bp sequencing.  VH:VL analysis for 
Donor 3 was performed using the same procedure with 0.5% LiDS in cell lysis buffer (as 
opposed to 1% LiDS as above) and leader peptide primers were used to test VH:VL 
pairing precision with a different human primer set (Table A2.4)
12
.  Analysis with a 
known ARH-77 VH:VL control cell spike was also performed using sorted and in vitro 
expanded memory B cells from one human donor, as described above.  This study was 
approved by the University of Texas at Austin Institutional Review Board (2012-08-
0031) and Institutional Biosafety Committee (2010-06-0084) and blood was drawn after 
informed consent had been obtained.  Cells were expanded in vitro as described above 
and ~260 ARH-77 immortalized cells were spiked into a sample of ~20,000 expanded 
memory B cells in 3 mL PBS; single-cell VH:VL analysis was then performed as above 
using 1% LiDS and Framework 1 primers.   
HEK293 cells were transfected with known antibodies as reported previously
82
 
(Table A2.1).  Pacific Biosciences single-molecule real-time sequencing was performed 
with VH:VL amplicons derived from week 119 CD27
+
 peripheral B cells of the CAP256 
donor
79
 using Framework 1 region primers. 
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3.4.4 BIOINFORMATIC ANALYSIS 
Raw Illumina sequences were quality-filtered, mapped to V-, D-, and J- genes and 
CDR3’s extracted using the International Immunogenetics Information System (IMGT)95.
Sequence data were filtered for in-frame V(D)J junctions and productive VH and V,
sequences were paired by Illumina read ID and compiled by exact CDR3 nucleotide and 
V(D)J gene usage match.  CDR-H3 nucleotide sequences were extracted and clustered to 
96% nt identity with terminal gaps ignored (USEARCH v5.2.32
122
) and resulting VH:VL
pairs with 2 reads comprised the list of VH:VL clusters for each data set.  To determine 
the complete VH:VL sequence of the entire approx. 850 nt amplicon by Illumina Miseq 
2x250 or 2x300, the separate VH and VL amplicons were sequenced as separate samples 
and CDR3 junction regions were used as anchors for consensus sequences of each 
VH:VL pair
82
.
Pacific Biosciences sequencing data were pre-processed with the PacBio SMRT 
Analysis suite followed by IMGT analysis of paired VH and VL regions.  Complete 
VRC26-class antibody variable region sequences were identified from PacBio circular 
consensus sequences via BLAST search (Table A2.6 and A2.7).  Allelically included 
sequences for Donors 1, 2, and 3 were detected using an iterative loop that identified 
heavy chain clusters paired with multiple light chains which were encoded by distinct 
V and J genes, and pairings were cross-confirmed in both replicates.  
DNA sequences can be downloaded from the NCBI Short Read Archive (SRA) 
under study accession number SRP047462, and computer source code is available in 
GitHub repository NMED-NT69968.  Randomization was performed by random number 
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generation and statistical comparisons performed using a single-factor analysis of 
variance followed by a Tukey’s HSD post-hoc test with two-tailed p-values (IBM SPSS 
v.20, Table A2.8).
Precision, P, (also called positive predictive value, PPV) is calculated from the 
number of true positives (TP) and false positives (FP)
123
:
𝑃 =
𝑇𝑃
𝑇𝑃 + 𝐹𝑃
True VH:VL pairs cannot be known for an entire human antibody repertoire, but 
we can approximate true positives and false positives with matched vs. mismatched 
VH:VL pairs in technical replicates.  We assume that a VH paired with the same VL in 
both replicates is a true positive in replicates 1 and 2 (TP1and2), conversely, we assume 
any VH paired with a different VL in the two replicates is a false positive in at least one 
replicate (FP1or2).  Thus the aggregate precision of two independently analyzed replicates 
1 and 2 is: 
𝑃1𝑎𝑛𝑑2 =
𝑇𝑃1𝑎𝑛𝑑2
(𝑇𝑃1𝑎𝑛𝑑2 + 𝐹𝑃1𝑜𝑟2)
Probability theory dictates that the joint probability of independent events is equal 
to the product of the independent event probabilities; additionally, pairing precision of 
technical replicates 1 and 2 (P1 and P2, respectively) are assumed to be equal as a 
property of technical replicates. 
𝑃1𝑎𝑛𝑑2 = 𝑃1 × 𝑃2 = 𝑃
2
We can combine the previous two equations and solve for P, the VH:VL pairing 
precision of a single analysis. 
70 
𝑃1𝑎𝑛𝑑2 = 𝑃
2 =
𝑇𝑃1𝑎𝑛𝑑2
(𝑇𝑃1𝑎𝑛𝑑2 + 𝐹𝑃1𝑜𝑟2)
𝑃 = √
𝑇𝑃1𝑎𝑛𝑑2
𝑇𝑃1𝑎𝑛𝑑2 + 𝐹𝑃1𝑜𝑟2
For a hypothetical experiment:  if 950 VH sequences were observed with 
matching VL in both groups (TP1and2 = 950) while 50 VH sequences displayed disparate 
VL in the two groups, VH:VL pairing precision P is estimated by P = (950/1,000)
0.5 
=
97.5%. 
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4. PAIRED VH:VL ANALYSIS OF NAÏVE B CELL REPERTOIRES
AND COMPARISON TO ANTIGEN-EXPERIENCED B CELL 
REPERTOIRES IN HEALTHY HUMAN DONORS 
4.1  Introduction 
Obtaining an extensive sequence database for the naïve B cell repertoire is of 
great importance for immunology and medical research because the ensemble of 
sequences that comprise the naïve repertoire will ultimately dictate whether an organism 
has the ability to recognize a particular chemical species.  Only when an antibody in the 
naïve repertoire can bind to antigen even with very low affinity, it becomes possible for 
the respective B cell to undergo stimulation and differentiation to ultimately produce 
soluble antibodies. The comprehensive interrogation and analysis of the naïve repertoire 
requires that both the natively paired VH and VL gene sequences (i.e. originating from 
individual B cells) are determined at high throughput.  However, limitations of standard 
high-throughput antibody repertoire sequencing technologies had so far limited 
comprehensive descriptions of paired heavy and light chain variable sequences  (VH:VL) 
in human naïve B cells. Earlier studies of human naïve B cell repertoires employed 
single-cell RT-PCR (Chapter 1) and as a result throughput was limited to at most 
approximately 10
3
 total B cell clones per experiment
124–126
. More recently, high-
throughput DNA sequencing methods have been applied for analysis the naïve B cell 
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repertoire
92,127,128
.  However, due to the limitations of high-throughput sequencing that
lead to loss of antibody heavy and light chain information (Chapter 1), these recent high-
throughput analyses were unable to analyze the complete heavy and light chain antibody 
clonotypes.  In particular, high-throughput VH:VL sequencing and structural analysis of 
both naïve and antigen-experienced B cell repertoires may uncover key differences across 
B cell subsets and lead to new insight on antibody clonal selection and development 
mechanisms.  Detailed knowledge of gene usage and biochemical or structural features 
for effective antibody development in healthy donors may also inform design of 
advanced immunogens for novel vaccine approaches
118,129,130
 or enhance our
understanding of aberrant antibody development and its role in autoimmune 
disease
40,131,24,132
.
 To address the aforementioned technical issues in high-throughput antibody 
sequencing we recently reported a new method that obtains paired heavy and light chain 
sequence information at very high throughput from single B cells (up to 5x10
6
 input cells
per sample)
83
.  Here, we apply this technique to analyze naïve B cell repertoires in three
separate healthy human donors and compared our results to previously reported data 
generated from antigen-experienced populations of the same blood samples.  In doing so, 
we observed distinct universal patterns of gene usage, biochemical metrics, and antibody 
structure that have never before been reported.  These data highlight the extensive 
similarities and key differences across human donors that comprise the adaptive immune 
response of our species. 
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4.2  Results 
4.2.1  VH:VL GENE USAGE ACROSS B CELL SUBSETS 
We analyzed the peripheral blood antibody repertoire of three human donors 
using the single B cell VH:VL sequencing technique reported and described in Chapter 
Four
83
.  Peripheral blood mononuclear cells (PBMC) isolated from three human donors
were sorted by FACS to discriminate CD3
-
19
+
20
+
27
-
 naïve B cell and CD3
-
19
+
20
+
27
+
antigen-experienced B cell populations.  Our sequencing method incorporated single-cell 
sequestration and lysis in emulsion droplets to capture single-cell heavy and light chain 
mRNA onto poly(dT) magnetic beads, followed by emulsion overlap extension RT-PCR 
that linked heavy and light chain sequences to generate a single heavy:light cDNA strand 
for high-throughput VH:VL DNA sequencing and analysis
83
.  We recovered a total of
55,355 unique naïve B cell sequences after VH:VL pairing using the technology 
described in Chapter Four and compared these data to 123,941 distinct CDR-H3:CDR-L3 
pairs recovered from antigen-experienced cells in the same donors (Table 4.1; antigen-
experienced raw data was previously reported and reprocessed for the present study
83
).
Naïve and antigen-experienced heavy/light paired V-gene usage were visualized by 
surface plots (Figure 4.1), and paired V-gene usage in antigen-experienced repertoires 
was further subdivided by heavy chain isotype for analysis (Figures A3.1 and A3.2). 
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Donor CD3
-
19
+
20
+
27
-
 Naïve CD3
-
19
+
20
+
27
+
 Ag-Exp 
1 13,780 34,692 
2 26,372 89,249 
3 15,203 - 
Total 55,355 123,941 
Table 4.1  Paired heavy:light B-cell receptor sequences recovered for naïve and antigen-
experienced (Ag-Exp) B cell subsets after 96% clustering and quality 
filtering of sequence data (see Methods).  Antigen-experienced raw data was 
re-processed alongside naïve B cell data for consistency
83
.
We applied Pearson hierarchical clustering to analyze the VH:VL repertoires for 
similarity in V-gene usage (Figure 4.2), which yielded several striking results:
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Figure 4.1 Paired heavy/light V-gene usage surface maps of sequenced antibody repertoires.  Consistent trends in gene usage 
were readily observed, and the antibody repertoires of each donor and subset were distinct.  Statistical analysis of 
VH:VL gene usage data presented here was performed with Pearson hierarchical clustering (Figure 4.2). 
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Figure 4.2 Clustergrams resulting from Pearson hierarchical cluster analysis of paired 
heavy and light chain V-gene usage in sequenced donor repertoires.  Panel 
(a) compares naïve repertoires to antigen-experienced repertoires, whereas 
panel (b) compares naïve repertoires to each of three antigen-experienced 
repertoire heavy chain isotype subsets (IgM, IgA, and IgG).  Relative 
distance is indicated by line heights connecting different groups. 
i. Naïve repertoires of different donors clustered together, and antigen-experienced
repertoires of different donors also clustered together as a separate grouping 
(Figure 4.2a).  These data indicated that V-gene usage in the naïve repertoire of a 
given donor was more similar to the naïve repertoire of other donors than it was 
to the antigen-experienced repertoire in the same individual.  
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ii. Upon further subclassification of antigen-experienced repertoires by heavy chain
isotype, we found that IgM repertoires across donors clustered as one grouping, 
and class-switched repertoires (IgG, IgA) clustered as another grouping (Figure 
4.2b).  Importantly, IgM repertoires were found to cluster in between the naïve 
and class-switched repertoires, which may be a direct consequence of IgM 
memory B cells serving as a transitional stage between mature naïve B cells and 
class-switched antigen-experienced B cells. 
iii. In contrast to naïve and ag-exp IgM B cell subsets, the ag-exp IgG and IgA
subsets revealed more individuality across donors.  Figure 4.2b shows that the 
class-switched IgG and IgA repertoires of Donor 1 were more similar to each 
other than to the complementary IgG or IgA repertoire in Donor 2. 
We also observed higher variability in IgK and IgL gene usage in naïve 
repertoires compared to antigen-experienced repertoires (Figure A3.3).  The variation in 
IgK:IgL usage may have caused a broader spread among the naïve repertoire cluster 
compared to the antigen-experienced cluster (Figure 4.2a). 
A longstanding question in antibody development is whether certain heavy/light 
V-gene combinations are favored or disfavored relative to what might be expected due to 
random VH:VL pairing given overall VH- and VL-gene expression in the repertoire.  
Presumably, any “holes” in VH:VL gene usage compared to overall VH:VL frequency 
expectation (i.e. compared to random VH:VL pairing expectation based on the fraction 
expression of each heavy and light V-gene) might indicate structural mismatch between 
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heavy and light chain V-genes that prevent successful display of B-cell receptors, or other 
functional implications (e.g. holes in naïve repertoire heavy/light V-gene pairing could 
arise from heavy/light V-gene structural mismatch or particularly autoimmunogenic 
combinations).  On the other hand, “peaks” in VH:VL gene usage could indicate a highly 
effective VH:VL gene pair (e.g. in ag-exp cells, a gene usage peak could result from 
VH:VL pairings that are protective against common pathogens).  We applied several 
statistical techniques in search of “holes” and “peaks” in all sequenced repertoires 
(namely linear model-based t-tests
133
, DESeq
134, and Student’s t-test).  Importantly, all
methods revealed no holes nor peaks in the repertoire with statistical significance given 
the sample sizes obtained in the present study.  While no statistical significance was 
observed across all three donors, several putative holes and peaks were observed within 
individual donors in both naïve and antigen-experienced subsets.  VH:VL pairing peaks 
and holes that were unique to each individual could have occurred by any combination of 
genetic variation, and environmental exposure, and sampling error, and the relative 
contributions of these three factors is unknown. 
Finally, we analyzed heavy/light V-gene combinations for V-gene pairs that were 
statistically enriched or depleted in antigen-experienced repertoires compared to the naïve 
repertoires using linear model-based t-tests
133
.  We found a total of 29 statistically
significant heavy/light V-gene pairings with an adjusted p-value less than 0.05 that 
indicated differences in gene expression between naïve and antigen-experienced groups 
(listed in Table A3.1).  Interestingly, many of these V-genes observed to be differentially 
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expressed in the paired heavy/light naïve and ag-exp repertoires were also observed with 
differential V-gene expression by separate heavy and light chain sequencing
92,127,128
.
4.2.2  CDR3 LENGTH ANALYSIS 
Prior studies have shown that CDR3 length decreases during B cell maturation 
into naïve B cells
12
 and again increases only slightly in naïve compared to antigen-
experienced repertoires
127
, and also single-cell RT-PCR studies found no strong
correlation between heavy and light chain lengths
124,135
.  We determined the CDR-H3 and
CDR-L3 lengths of naïve and antigen-experienced repertoires and compared our results 
to previous studies.  First, we observed that the average CDR-H3 length was slightly 
lower in antigen-experienced repertoires compared to naïve repertoires, however the 
averages and medians were very similar. Importantly, the CDR-H3 length distribution 
was markedly narrower in antigen-experienced compared to naïve B cells, and these 
differences were significant by the Kolmogorov–Smirnov test for probability distribution 
analysis (p < 10
-14
, Figure 4.3a).  In contrast, CDR-L3 length distributions showed more
similarity across repertoires (Figure 4.4b), and broader error bars in naïve CDR-L3 
lengths resulted from variability in IgK and IgL gene usage in naïve repertoires (Figure 
A3.3) because IgK and IgL possess distinct CDR-L3 length distributions (maxima at 9aa 
in IgK versus 11aa in IgL). 
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Figure 4.3 Distribution histograms (average  standard deviation) for (a) CDR-H3 amino 
acid length, and (b) CDR-L3 amino acid length, averaged across all three 
donors.   
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Finally, we observed no strong correlation in paired heavy and light chain CDR3 loop 
lengths, similar to previous reports
124,135
 (Figure A3.4), suggesting that antibody heavy
and light chain sequences pair randomly with respect to CDR3 length. 
4.2.3  CDR3 CHARGE
Previous reports have observed increases in average CDR-H3 positive charges in 
antigen-experienced repertoires compared to naïve repertoires
127
, and we inspected the
CDR3 charge distributions in our data to see if paired heavy and light chain CDR3 
displayed similar charge features compared to these heavy chain-only observations.  Both 
naïve and antigen-experienced repertoires exhibited charge distributions with maxima at 
neutral charge, with 90% of the repertoire falling between +2 and -2 by total CDR3 loop 
charge (Figure 4.4a).  We observed that the antigen-experienced repertoire was enriched 
for positive charges compared the naïve repertoires on an overall CDR-H3:CDR-L3 basis 
(Figure 4.4a), on a heavy chain-only basis (Figure 4.4b), and on a light chain basis 
(Figure 4.4c); differences in charge distribution for all three naïve:antigen-experienced 
repertoire comparisons in Figure 4.4 were statistically significant by the K-S test (p < 10
-
14
).  B-cell receptors with charge extremes were also slightly more prevalent in antigen-
experienced repertoires (6, 5, and 4 in the CDR-H3:CDR-L3, CDR-H3, and CDR-L3, 
respectively) however small sample size at charge extremes makes these observations 
subject to high sampling error.  We also observed distinct differences in CDR-L3 charge 
between kappa and lambda light chain repertoire subsets.  In the naïve repertoire, the 
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majority of kappa and lambda light chain CDR3 loops were close to neutral charge, 
however naïve kappa light chains showed a median charge of zero compared to lambda 
light chains with a median charge of negative one (Figure A3.5).  Interestingly, kappa 
light chains were strongly selected for enhanced positive charge in antigen-experienced 
repertoires, whereas lambda light chains showed enhancement of charge extremes (both 
positive and negative) in antigen-experienced repertoires.  Importantly, we note that 
Donor 1 and Donor 2 both displayed enhanced positive CDR3 charges in antigen-
experienced repertoires when compared to their naive repertoires (Figure A3.6).  The 
enhancement of positive charge in both heavy and light CDR3 loops concurrently is 
presented as a heat map in Figure A3.7. 
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Figure 4.4 CDR3 charge distribution for naïve and antigen-experienced repertoires 
(average  standard deviation) in (a) total CDR-H3 and CDR-L3 charge, (b) 
CDR-H3 charge, and (c) CDR-L3 charge.  Differences in charge distribution  
between naïve and antigen-experienced repertoires for all three panels were 
statistically significant by the K-S test (p < 10
-14
)
In terms of CDR3 charge we again observed distinct patterns across the lambda 
and kappa light chain repertoires.  In the naïve repertoire, the majority of kappa and 
lambda CDR-L3 were close to neutral charge, however kappa CDR-L3 had a median 
charge of zero compared to lambda CDR-L3 which showed a median charge of negative 
one.  Antigen-experienced kappa light chains were also more strongly selected for 
positive charges, compared to the somewhat weaker charge selection and enhancement of 
both positive and negative charge extremes in lambda light chains (Figure A3.5).  
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4.2.4  CDR3 HYDROPHOBICITY 
We analyzed the average hydrophobicity per residue (avg H-index) in paired 
CDR-H3 and CDR-L3 loops
136
.  We found that mean hydrophobicity decreased in
antigen-experienced BCR relative to naïve BCR on a heavy chain basis (0.0476  0.002 
for naïve, compared to 0.0389  0.006 for antigen-experienced).  However, the CDR-H3 
hdyrophobicity distribution peak shifted toward a moderately positive H-index in 
antigen-experienced repertoires, indicating enrichment of moderately hydrophobic CDR-
H3s in antigen-experienced repertoires (average H-index between 0 and 0.1, Figure 4.5).  
These trends were replicated in both Donor 1 and Donor 2, and especially highly 
hydrophobic CDR-H3 were depleted in the antigen-experienced repertoires while lower 
hydrophobicity CDR-H3s were well-tolerated. 
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Figure 4.6 CDR-H3 loop average hydrophobicity (avg H-index  standard deviation) 
distributions in naïve and antigen-experienced repertoires. 
Regarding CDR-L3 hydrophobicity we again observed strong differences between 
the kappa and lambda repertoires.  Overall, lambda light chain CDR3s were much more 
hydrophobic than kappa CDR3s, and these patterns were consistent across donors (Figure 
4.7).   We also observed that kappa light chains were strongly selected for enhanced 
hydrophobity indices and to a much greater extent than lambda light chains within the 
same donor (Figure 4.7).  As lambda light chain distributions showed little differences 
between naïve and antigen-experienced repertoires apart from a broadening of the H-
index distribution, we observed that kappa CDR-L3 are under stronger H-index positive 
selection pressure than lambda light chains, perhaps because of the much lower starting 
hydrophobicity of kappa light chains. 
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Figure 4.7 CDR-L3 loop average hydrophobicity indices in naïve and antigen-experienced antibody repertoires for Donor 1 
(left) and Donor 2 (right), subdivided by IgK (top) and IgL (bottom).  Kappa and lambda repertoires exhibited 
distinct CDR-L3 average hydrophobicity distributions (top compared to bottom graphs), and kappa light chains 
showed enhanced CDR-L3 hydrophobicity in antigen-experienced repertoires.  All four naïve repertoires were 
statistically significant from antigen-experienced repertoires in terms of CDR-L3 average H-index by the K-S test 
(p < 10
-12
); n for the above repertoires is provided in Table A3.2.
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4.2.5  PUBLIC HEAVY AND LIGHT CHAIN SEQUENCES 
Previous reports highlighted the existence of promiscuous and public light chain 
CDR3 antibody sequences in human immune repertoires due the lower diversity encoded 
by light chain VL junctions
83,108
.  Consistent with these earlier studies, we found
widespread promiscuous and public VL junctions in naïve repertoires by both amino acid 
and nucleotide sequences.  For example, 68.4  4.5 percent of naïve BCR were encoded 
by a promiscuous nucleotide CDR-L3 junction (i.e. a VL junction also expressed by at 
least one other BCR in the same donor), whereas 78.5  4.0 percent were encoded by a 
promiscuous amino acid CDR-L3 junction.  SHM dramatically reduced the fraction of 
promiscuous VL junctions observed in antigen-experienced repertoires (30.2  3.9 
percent by nucleotide basis, 46.9  5.7 by amino acid basis), however a significant 
fraction of antigen-experienced light chains were still encoded by promiscuous VL 
sequences in the ag-exp repertoires.  Despite widespread promiscuity observed in VL 
nucleotide sequences, we observed very few public CDR-H3 nucleotide sequences across 
individuals (three among all naïve donors), similar to previous reports
2,92
.
While public CDR-H3 nucleotide sequences are extremely rare across individuals, 
public CDR-H3 amino acid sequences are known to occur as a result of similar antibody 
responses to common antigens via vaccination or infection
78,120,121,131
.  We observed a
total of 23 exact amino acid match CDR-H3 amino acid junctions among naïve 
repertoires, and 63 amino acid exact match CDR-H3 among antigen-experienced 
repertoires.  We expected public amino acid CDR-H3 lengths to be significantly shorter 
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than that of the overall repertoire because short sequences have lower theoretical 
diversity and therefore a higher probability of repetition by random occurrence, and 
indeed this was the case (Figure 4.8).  However, while VH, VL, and JL gene usage was 
very different in naïve public CDR-H3 aa pairs, we observed a marked increase in 
convergent gene usage across individuals in the antigen-experienced repertoires (Figure 
4.9).  The relatively high  frequency of cognate light chain gene usage convergence in the 
public antigen-experienced CDR-H3 aa sequences (59% matching VL genes across 
antigen-experienced antibodies encoding the same CDR-H3) suggested a functional 
selection for these public, antigen-experienced BCR.  In contrast, the mostly incongruent 
VL gene usage that we observed among the naïve public CDR-H3 set (13% matching VL 
genes across naïve antibodies encoding the same CDR-H3) suggested random or 
“incidental” sequence convergence of the heavy chain CDR-H3 amino acid sequences 
without functional selection.  Importantly, distinct patterns of N/P addition, SHM, and 
distinct CDR-L3 lengths across donors (despite identical light chain V- and J- gene 
usage) demonstrated that the convergent public VH:VL clonotypes in antigen-
experienced repertoires derived from biologically distinct V-D-J and V-J recombination 
events (Table A3.2).  
89 
Figure 4.8 CDR-H3 length comparisons between overall repertoires and public CDR-H3 
amino acid sequences (average  standard deviation).  Values above each 
column indicate the total number of CDR-H3 in each group. 
Figure 4.9 Gene usage comparisons between public CDR-H3 amino acid.  Values above 
each column indicate the total number of public CDR-H3 in each group. 
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4.3 Discussion 
Our high-throughput paired heavy and light chain analysis of the human naïve 
antibody repertoire yielded extensive information on the composition of the human naïve 
repertoire and the universal shifts in heavy:light antibody repertoire characteristics as 
naïve B cells mature into antigen-experienced cells.  We found VH:VL gene usage was 
distinct among the various B cell subsets, even across multiple human donors (Figure 
4.2a), indicating that universal mechanisms direct paired V-gene usage throughout the 
transition from naïve to antigen-experienced IgM to class-switched B cells.  We also 
observed that IgM naïve and antigen-experienced repertoires showed higher VH:VL gene 
usage similarity across donors than to other B cell subsets isolated in the same individual, 
whereas V-gene usage in class-switched IgG and IgA repertoires was more similar within 
donors than across donors (Figure 4.2b).  This result suggested that the naïve repertoire 
and IgM antigen-experienced repertoires of different donors have similar composition, 
whereas environmental exposure (which is different for each individual) manifests most 
strongly in the class-switched repertoire.  As expected, we found that IgM VH:VL gene 
usage clustered in between naïve and antigen-experienced cells, which was highly 
consistent with the fact that IgM antigen-experienced cells can be considered a 
transitional stage between the naïve and class-switched repertoires.  Our analysis of intra- 
and inter-donor V-gene usage confirmed prior reports that highlighted universal 
regulation across antibody repertoire subsets
137
 and provided additional information
regarding paired heavy/light usage across multiple donors and B cell subsets. 
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We also inspected naïve and antigen-experienced repertoires for evidence of 
preferential pairings or prohibited pairings between heavy and light chain V genes.   
Though preferential V-gene pairings were detected within individual repertoires, we 
found no statistically significant preferential heavy and light chain pairs across human 
donors.  Structural mismatch between certain heavy and light chains V genes could still 
occur with a magnitude of effect smaller than detection limits for the approx. 55,000 
naïve sequences analyzed in this experiment.  Heavy/light pairing bias may also have 
predominantly affected only those V-genes with low expression in the repertoire and 
therefore with low total observations, or pairing bias observed in individual repertoires 
may have resulted from sampling variation or genetic and environmental differences 
across individuals.  In summary, our data suggested that heavy and light chain V-genes 
pair randomly – and for the most part, successfully – according to overall V-gene 
prevalence in B cell repertoires. 
We also observed that the biochemical composition of heavy and light chains was 
altered during the process of B-cell selection.  In particular, CDR-H3 length distribution 
narrowed slightly (consistent with previous reports
127
) while CDR-L3 lengths remained
largely unchanged after maturation to antigen-experienced B cells (Figure 4.3), indicating 
that the highly utilized CDR3 loop lengths are optimal for binding to most antigens.  Both 
heavy and light chain CDR3 charges increased in antigen-experienced repertoires (Figure 
4.4), and slight differences in charge composition were observed between kappa and 
lambda repertoires (Figure A3.5).  We hypothesize that the general increases in antibody 
charges may better enable binding to negatively charged bacterial membranes for anti-
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bacterial antibodies.  Importantly, we found that increases in H3 and L3 charge often 
occurred concurrently (Figure A3.7), suggesting similar selection pressure toward 
enhanced positive charges on both CDR-H3 and CDR-L3 loops.  We also observed that 
kappa light chains appeared to be more strongly selected for positive charge in the 
antigen-experienced repertoire compared to lambda light chains, despite the fact that 
kappa light chains are overall more positively charged in the baseline naïve repertoire 
(Figure A3.7).  These results suggest that kappa CDR3 loops may be slightly more 
effective at carrying positive charges and/or binding to negatively charged epitopes than 
lambda light chains.   
We also observed that total hydrophobicity of CDR-H3:CDR-L3 loops increased 
slightly, which may help enhance antibody binding affinity in the antigen-experienced 
repertoire.  Hydrophobicity in kappa light chain CDR3s was strongly increased in 
antigen-experienced repertoires compared to only minor changes is lambda light chain 
CDR3 hydrophobicity as a result of positive B cell selection (Figure 4.7).  These data 
highlighted the important differences between kappa and lambda light chains – namely, 
that kappa light chains are overall much less hydrophobic in the CDR3 and that selection 
pressures causes a general increase in kappa hydrophobicity, whereas lambda light chains 
start slightly more hydrophobic and are under somewhat less selection pressure for 
hydrophobicity.   
We noted several key differences in CDR3 length, charge, and hydrophobicity 
between kappa and lambda light chains, and these differences may serve important 
functional purposes.  For example, receptor editing is known to mitigate self-targeting of 
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autoimmunogenic antibodies
111,113,114
.  By having two different light chain gene sets –
each with a distinct distributions of properties in terms of CDR3 length, charge, and 
hydrophobicity – the immune system can have a greater likelihood of altering binding 
specificity by editing the light chain isotype.  These differences between kappa and 
lambda repertoires may also have functional importance in allelic inclusion because 
kappa and lambda allelically-included antibodies are more likely to show different 
binding specificities given their distinct biochemical composition
83,111,113–115
.  These
distinctions observed for kappa and lambda light chains across multiple B cell subsets 
and healthy human donors highlight the potentially unique and complementary roles that 
kappa and lambda light chains may play in the immune repertoire. 
Finally we note that strong similarities were observed across human donors:  the 
antibody repertoires recovered from different donors displayed convergence in 
heavy/light V-gene usage and biochemical metrics (e.g. loop length, charge, 
hydrophobicity, etc.), and a large fraction of light chains were also shared across donors 
and within donors.  We found that approximately 70 percent of naïve light chains were 
encoded by a promiscuous nucleotide sequence while nearly 80 percent of naïve light 
chains were encoded by a promiscuous amino acid sequence, and even around 50 percent 
of antibodies in antigen-experienced repertoires were encoded by public CDR-L3 amino 
acid sequences. These data demonstrated that light chain high-throughput sequencing 
without heavy chain pairing information is inadequate for accurate characterization of the 
true light chain repertoire, as traditional high-throughput sequencing cannot distinguish 
between identical light chains that are encoded by multiple B cell clonotypes.  We also 
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observed a small number of public heavy chain CDR3 amino acid sequences in both 
naïve and antigen-experienced repertoires.  While naïve public CDR-H3 often exhibited 
disparate VH-gene and VL-gene usage (though nearly always the same JH genes), the 
antigen-experienced public CDR-H3 showed a strong enhancement in convergent gene 
usage (Figure 4.9).  The convergent gene usage in public antigen-experienced CDR-H3 
suggested that population-wide functional selection may result in similar public 
antibodies generated across multiple individuals, as suggested by previous 
reports
78,120,121,131
.
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4.4  Methods 
4.4.1 ETHICS STATEMENT 
Informed consent was obtained from anonymous donors prior to experiments by 
the Gulf Coast Regional Blood Center (Houston, TX).  This study was approved by the 
University of Texas at Austin Institutional Biosafety Committee (2010-06-0084). 
4.4.2 CELL ISOLATION AND VH:VL PAIRING 
PBMC were isolated from donated human whole blood and non-B cells were 
depleted via magnetic bead sorting (Miltenyi Biotec, Auburn, CA).  B cells were stained 
with anti-CD20-FITC (clone 2H7, BD Biosciences, Franklin Lakes, NJ, USA), anti-CD3-
PerCP (HIT3a, BioLegend, San Diego, CA, USA), anti-CD19-v450 (HIB19, BD), and 
anti-CD27-APC (M-T271, BD).  CD3
-
CD19
+
CD20
+
CD27
-
 naïve B cells were analyzed
for VH:VL sequences immediately following FACS sorting.  CD3
-
CD19
+
CD20
+
CD27
+
antigen-experienced B cells (comprised of mostly memory B cells with a small number 
of peripheral plasmablasts) were incubated four days in the presence of RPMI-1640 
supplemented with 10% FBS, 1× GlutaMAX, 1× non-essential amino acids, 1× sodium 
pyruvate and 1× penicillin/streptomycin (LifeTechnologies) along with 10 µg/mL anti-
CD40 antibody (5C3, BioLegend), 1 µg/mL CpG ODN 2006 (Invivogen, San Diego, CA, 
USA), 100 units/mL IL-4, 100 units/mL IL-10, and 50 ng/mL IL-21 (PeproTech, Rocky 
Hill, NJ, USA)
41
 prior to high-throughput VH:VL sequencing.  High-throughput
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emulsion-based VH:VL sequencing was performed as reported previously
83
.  Briefly,
cells were isolated into emulsion droplets along with poly(dT) magnetic beads for mRNA 
capture using a flow-focusing nozzle apparatus.  Droplets contained lithium dodecyl 
sulfate and DTT to lyse cells and inactivate proteins, and mRNA released from lysed 
cells was captured by the poly(dT) sequences on magnetic beads.  The emulsion was 
broken chemically and beads were collected, washed, and used as template for emulsion 
overlap extension RT-PCR which linked heavy and light chain transcripts into a single, 
linked cDNA construct for high-throughput sequencing.  All VH:VL pairing analyses 
used primers targeting the Framework 1 antibody gene regions
82
.
4.4.3 BIOINFORMATIC ANALYSIS 
Raw Illumina sequences were quality-filtered, mapped to V-, D-, and J- genes and 
CDR3s extracted using both the International Immunogenetics Information System 
(IMGT)
95 
and NCBI IgBlast software
138
 with a CDR3 motif identification algorithm
52
.
Most antibody sequences were successfully mapped by both algorithms (96% of all 
sequenced antibodies), and IMGT gene assignments were given priority over IgBlast 
assignments.  Sequence data were filtered for in-frame V(D)J junctions and productive 
VH and V, sequences were paired by Illumina read ID and compiled by exact CDR3 
nucleotide and V(D)J gene usage match.  CDR-H3 nucleotide sequences were extracted 
and clustered to 96% nt identity with terminal gaps ignored (USEARCH v5.2.32
122
), with
a minimum of one nucleotide mismatch permitted during CDR-H3 clustering regardless 
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of sequence length.  Resulting VH:VL pairs with 2 reads comprised the preliminary list 
of VH:VL clusters for each data set.  For determining germline identity in the FR3 
region, all FR3 reads associated with the VH and VL in a given VH:VL pair were 
clustered by 90% identity using USEARCH
122
, and the largest of the resulting clusters
were analyzed by alignment of these representative FR3 sequences with IMGT to 
determine percent homology to known germline genes. Naïve antibody sequences were 
additionally filtered to include only those sequences with >98% germline identity in the 
FR3 region, similar to previous reports
92
.  Amino acid sequence hydrophobicity was
determined by the normalized version of the Kyte-Doolittle hydrophobicity index
136
;
antibody isotypes were determined by analyzing constant region sequences. 
4.4.4 STATISTICAL ANALYSIS 
R (version 3.1.1) was used for hierarchical clustering (function “hclust”), the 
Kolmogorov-Smirnov test (function “ks.test”), and the identification of differentially 
paired genes (package “limma” version 3.14.4)133,139.  For hierarchical clustering the
fractional frequency of V-gene pairs was multiplied by a scaling factor of 100,000.  After 
discarding gene pairs with zero fraction, the fractions were log2-transformed and normal 
distributions were generated. Distance between samples was measured by Pearson 
correlation with complete-linkage as the agglomerative method. For Kolmogorov-
Smirnov (K-S) test, raw values such as charge, length, hydrophobicity were used to 
compare probability distributions across experimental groups. Although the Linear 
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Models for Microarray Data method (limma) was originally developed to identify 
differentially expressed genes in microarray data, the algorithm is also applicable to 
quantitative PCR or RNA-Seq that provides a matrix composed of genes and expression 
values, and the linear model-based test is stable for experiments with a small number of 
replicates in that it borrows information across genes.  Before running limma, gene pairs 
with zero usage were removed and quantile normalization was performed to normalize 
the difference in distribution of values among samples. P-values for multiple 
comparisons were corrected with the Benjamini-Hochberg procedure.  Differentially 
paired gene cut-offs were established at a fold change of 2 and an adjusted p-value of 
0.05. 
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5. CONCLUSIONS AND FUTURE PERSPECTIVES
We developed and validated a new technology for high throughput sequencing of 
paired antibody heavy and light chains at very high cell throughput.  This work was 
undertaken specifically to address a critical deficiency in currently available high 
throughput antibody sequencing techniques, namely that the pairing information of heavy 
and light chains is irreversibly lost during traditional high-throughput sequencing.  We 
first reported a microarray-based technique with capacity for up to 10
5
 cells per
analysis
82
, then translated the same general workflow into emulsion droplets for
interrogation of up to 10
7
 single B cells per operator in a single day
83
.  We determined the
VH:VL pairing accuracy of our technique to be >97%
83
 and applied our technology for
antibody discovery
65,79,82,140
, proteomic analysis of vaccine responses
65,69
, mechanistic
investigation of HIV broadly neutralizing antibody development
79
, and to generate novel
immunological insight related to the composition and development of antibody 
repertoires in healthy human donors
83,141
.
Importantly, our method for sequencing multiple mRNAs from single cells has a 
number of applications beyond the sequencing of antibody heavy and light chain pairs.  
Future efforts in this area will incorporate additional mRNAs of interest, for example 
pairing of transcription factors implicated in B-cell development such as Blimp-1
39
 to
determine both B cell maturity and VH:VL sequences in a single experiment without the 
need for fluorescence-activated cell sorting (FACS).  As FACS is an expensive and time-
consuming task that requires skilled operators, the ability to omit FACS for separate 
analysis of cell subsets may enable faster, cheaper, and therefore more effective 
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investigations of human adaptive immune repertoires.  We will also analyze paired 
antibody VH:VL sequences of cells with surface expression of a particular phenotype, for 
example B-cell receptor affinity to an antigen of interest for extremely rapid and high-
throughput antibody discovery. 
Our accessible technology for sequencing the paired antibody VH:VL repertoire 
enables rapid interrogation of the immune response and can be applied to investigate B-
cell responses in a variety of clinical and research settings.  In particular, the suite of new 
techniques presented here will greatly enhance high-throughput, high-resolution analysis 
of human vaccine responses, providing new ways to test vaccine efficacy and thereby 
inform vaccine design.  The high-throughput identification and cloning of paired VH:VL 
antigen-specific antibodies from responding B cells may also enable rapid generation of 
novel diagnostic, therapeutic or prophylactic antibodies.  As DNA sequencing 
technologies continue to progress, low-cost high-throughput single-cell antibody 
sequencing can enable paired antibody repertoire analysis at great depth in large study 
cohorts and clinical patients and in turn provide unprecedented insights into humoral 
responses associated with vaccine development, autoimmunity, infectious diseases and 
other human disease states. 
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Appendix 1 – Chapter 2 Supplementary Information 
 
Figure A1.1 An overview of the linkage (overlap extension) RT-PCR process.  a) V-
region primers (black) with a 5’ complementary heavy/light overlap region 
(green) anneal to first strand cDNA.  b) Second strand cDNA is formed by 
5’ to 3’ extension; the overlap region is incorporated into all cDNA.  c) 
After denaturation, heavy and light chains with first strand sense anneal to 
generate a complete 850 bp product through 5’ to 3’ extension.  The CDR-
H3 and CDR-L3 are located near the outside of the final linked construct to 
allow CDR3 analysis by 2x250 paired-end Illumina sequencing.  Linkage 
RT-PCR primer sequences are given in Table A1.5 (V-region primers 
denoted “fwd-OE” and constant region primers denoted “rev-OE”). 
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Immunization n/a Tetanus Toxoid (TD, MSD) Influenza (2010-11 Fluvirin) 
Cell Type IgG
+
 B lymphocytes Day 7 post-TT boost TT
+
 plasmablasts Day 14 memory B cells 
Fresh Cells vs. Freeze/Thaw Fresh Freeze/Thaw Freeze/Thaw 
Cell:Well Ratio 1:10 1:425 1:39 
% cells as single cells 95.1% 99.9% 98.7% 
Unique CDR-H3 Recovered 2,716 86 240 
Control Cell Spike IM-9 ARH-77 IM-9 
Accuracy Ratio
1
 78:1 650:1 942:1 
1 
For known spiked cells, (reads correct VL):(reads top incorrect VL) 
Table A1.1 Key statistics from several paired VH:VL repertoires.  TD-tetanus toxoid/diphtheria toxoid, MSD-Merck Sharpe & 
Dohme 
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Figure A1.2 A heat map of VH:VL pairings from IgG
+
 class-switched peripheral B cells
isolated from a healthy volunteer (n=2,248).  The experiment presented here 
is a replicate of Fig. 2a using donated blood from a different individual. 
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Immunization n/a 
Cell Type IgG
+
 B lymphocytes 
Fresh Cells vs. Freeze/Thaw Fresh 
Cell:Well Ratio 1:10 
% cells as single cells 95.1% 
Unique CDR-H3 Recovered 2,248 
Control Cell Spike IM-9 
Accuracy Ratio
1
 125:1 
1 
For known spiked cells, (reads correct VL):(reads 
top incorrect VL) 
Table A1.2 Key statistics for the IgG+ VH:VL pairing experiment from a second 
volunteer (Fig. A1.2). 
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Seq ID Isotype CDR-H3 Paired CDR-L31 Source 
2D02 IgM gcgagaggcggaaatgggcgaccctttgacaac gcagcatgggatgacagcctgaatggttgggtg Sanger scRT-PCR 
2D02 IgM gcgagaggcggaaatgggcgaccctttgacaac gcagcatgggatgacagcctgaatggttgggtg MiSeq VH:VL 
3D05 IgM gcgagaaggtactttgactac gnagcatgggatgacagcctgaatgtttggntg Sanger scRT-PCR 
3D05 IgM gcgagaaggtactttgactac gcagcatgggatgacagcctgaatgtttggctg MiSeq VH:VL 
1E02 IgG1 gcgcgacatggccctgcgggaaaaagcgcgtatggttttgatatc cagtcctatgacagcggactgaatggttatgtggtc Sanger scRT-PCR 
1E02 IgG gcgcgacatggccctgcgggaaaaagcgcgtatggttttgatatc cagtcctatgacaacagactgaatggttatgtggtg MiSeq VH:VL 
3A01 IgG3 gcgagagtaatagcagctcgcgaccgccggatcactcctaactactaccgccctatggacgtc caggtgtgggatagtagtagtgaccatcaggtg Sanger scRT-PCR 
3A01 IgG gcgagagtaatagcagctcgcgaccgccggatcactcctaattactaccgccctatggacgtc caggtgtgggacagtagtagtgatcatcaggtg MiSeq VH:VL 
1 
The 2D02 and 3D05 CDR-L3 sequences are highly similar but differ by two bases 
Table A1.3 Analysis of overlapping heavy chain sequences and paired light chain sequences identified by both single cell RT-PCR 
and high-throughput VH:VL pairings in a memory B cell population isolated from an individual 14 days post-vaccination 
with the 2010-2011 trivalent FluVirin influenza vaccine.  
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Figure A1.3 As Fig. 2b comprised the lowest sample size in Figure 2.2 (n=86 unique pairs, compared to Fig. 2a, n=2,716, and Fig. 2c, 
n=240) a simulation was performed to randomly select 86 VH:VL pairs from Fig. 2a and 2c and normalize all panels to 
86 unique sequences.  (a) healthy donor peripheral IgG
+
 B cells, (b) day 7 tetanus-toxoid specific plasmablasts, and (c)
day 14 post-influenza vaccination memory B cells.  The simulation presented here facilitates comparison between panels 
a, b, and c. 
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Experiment 
Resting IgG+ 
repertoire 
Tetanus toxoid D7 
plasmablasts 
Figure 2.2a 2.2b 
Cell:Well Ratio 1:10 1:425 
Fraction Single Cells
1
 0.951 0.999 
Spiked Clone IM-9 ARH-77 
Spike % 4.0 7.5 
Estimated # spiked cells 2,830 30 
Estimated Spiked Cells as Single Cells
1 2,691 30 
Estimated Spiked Cells as 2-cells-per-well
1
 139 0 
Paired Reads in Dataset 287,572 30,238 
Correctly Paired Spike VH:VL Reads 14,805 871 
Predicted Mispairing Rate
1
 4.9% 0.1% 
Spike VH : Top Non-Spike VL Mispairing Rate 1.3% 0.15% 
Top Non-Spike VH : Spike VL Mispairing Rate 7.8% 0.31% 
Total Recovered VH:VL Pairs From Sample 2,716 86 
1 
Calculated from the Poisson distribution 
Table A1.4 Statistical analysis of pairing accuracy
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Table A1.5 Overlap Extension (OE) RT-PCR primer mix 
Conc. (nM) Primer ID Sequence 
400 CHrev-AHX89 CGCAGTAGCGGTAAACGGC  
400 CLrev-BRH06 GCGGATAACAATTTCACACAGG  
40 hIgG-rev-OE-AHX89 CGCAGTAGCGGTAAACGGC AGGGYGCCAGGGGGAAGAC  
40 hIgA-rev-OE-AHX89 CGCAGTAGCGGTAAACGGC CGGGAAGACCTTGGGGCTGG 
40 hIgM-rev-OE-AHX89 CGCAGTAGCGGTAAACGGC CACAGGAGACGAGGGGGAAA 
40 hIgKC-rev-OE-BRH06 GCGGATAACAATTTCACACAGG GATGAAGACAGATGGTGCAG  
40 hIgLC-rev-OE-BRH06 GCGGATAACAATTTCACACAGG TCCTCAGAGGAGGGYGGGAA  
40 hVH1-fwd-OE TATTCCCATGGCGCGCCCAGGTCCAGCTKGTRCAGTCTGG  
40 hVH157-fwd-OE TATTCCCATGGCGCGCCCAGGTGCAGCTGGTGSARTCTGG  
40 hVH2-fwd-OE TATTCCCATGGCGCGCCCAGRTCACCTTGAAGGAGTCTG  
40 hVH3-fwd-OE TATTCCCATGGCGCGCCGAGGTGCAGCTGKTGGAGWCY  
40 hVH4-fwd-OE TATTCCCATGGCGCGCCCAGGTGCAGCTGCAGGAGTCSG  
40 hVH4-DP63-fwd-OE TATTCCCATGGCGCGCCCAGGTGCAGCTACAGCAGTGGG  
40 hVH6-fwd-OE TATTCCCATGGCGCGCCCAGGTACAGCTGCAGCAGTCA  
40 hVH3N-fwd-OE TATTCCCATGGCGCGCCTCAACACAACGGTTCCCAGTTA  
40 hVK1-fwd-OE GGCGCGCCATGGGAATAGCCGACATCCRGDTGACCCAGTCTCC  
40 hVK2-fwd-OE GGCGCGCCATGGGAATAGCCGATATTGTGMTGACBCAGWCTCC  
40 hVK3-fwd-OE GGCGCGCCATGGGAATAGCCGAAATTGTRWTGACRCAGTCTCC  
40 hVK5-fwd-OE GGCGCGCCATGGGAATAGCCGAAACGACACTCACGCAGTCTC  
40 hVL1-fwd-OE GGCGCGCCATGGGAATAGCCCAGTCTGTSBTGACGCAGCCGCC  
40 hVL1459-fwd-OE GGCGCGCCATGGGAATAGCCCAGCCTGTGCTGACTCARYC  
40 hVL15910-fwd-OE GGCGCGCCATGGGAATAGCCCAGCCWGKGCTGACTCAGCCMCC 
40 hVL2-fwd-OE GGCGCGCCATGGGAATAGCCCAGTCTGYYCTGAYTCAGCCT  
40 hVL3-fwd-OE GGCGCGCCATGGGAATAGCCTCCTATGWGCTGACWCAGCCAA  
40 hVL-DPL16-fwd-OE GGCGCGCCATGGGAATAGCCTCCTCTGAGCTGASTCAGGASCC  
40 hVL3-38-fwd-OE GGCGCGCCATGGGAATAGCCTCCTATGAGCTGAYRCAGCYACC  
40 hVL6-fwd-OE GGCGCGCCATGGGAATAGCCAATTTTATGCTGACTCAGCCCC  
40 hVL78-fwd-OE GGCGCGCCATGGGAATAGCCCAGDCTGTGGTGACYCAGGAGCC  
Conc. (nM) Primer ID Sequence 
400 hIgG-all-rev-OEnested ATGGGCCCTGSGATGGGCCCTTGGTGGARGC 
400 hIgA-all-rev-OEnested ATGGGCCCTGCTTGGGGCTGGTCGGGGATG 
400 hIgM-rev-OEnested ATGGGCCCTGGGTTGGGGCGGATGCACTCC 
400 hIgKC-rev-OEnested GTGCGGCCGCAGATGGTGCAGCCACAGTTC 
400 hIgLC-rev-OEnested GTGCGGCCGCGAGGGYGGGAACAGAGTGAC 
Table A1.6 Nested PCR primers. 
113 
Conc. (nM) Primer ID Sequence 
400 hIgG-all-rev-OEnested ATGGGCCCTGSGATGGGCCCTTGGTGGARGC 
400 hIgA-all-rev-OEnested ATGGGCCCTGCTTGGGGCTGGTCGGGGATG 
400 Linker-VHfwd-BC2 NNNNTGAAGGGGCTAGCTATTCCCATCGCGG 
400 hIgKC-rev-OEnested GTGCGGCCGCAGATGGTGCAGCCACAGTTC 
400 hIgLC-rev-OEnested GTGCGGCCGCGAGGGYGGGAACAGAGTGAC 
400 Linker-VLfwd-BC2 NNNNTGAAGGGCGCCGCGATGGGAAT 
Table A1.7 VH and VL Separate Amplification Primers 
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Figure A2.1 A micrograph of the axisymmetric flow-focusing nozzle during emulsion 
generation (left), placed in context of the diagram from Figure 2.1a (right), 
where PBS/0.4% Trypan blue exits the inner needle and cell lysis buffer 
exits the outer needle. 
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Figure A2.2 MOPC-21 immortalized B cells encapsulated in emulsion droplets.  The 
outer aqueous stream that normally contains cell lysis buffer (Fig. 1a, gray 
solution) was replaced with 0.4% Trypan blue in PBS to examine cell 
viability throughout the flow focusing and emulsification process.  
Emulsified cell viability was approximately 90% and cell viability did not 
differ substantially from non-emulsified controls. 
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Figure A2.3 Heat map of V-gene usage for 129,097 VH:VL clusters recovered from Donor 1.  Sequences were collected using primers 
targeting the framework 1 region; raw data is available in the online supplement. 
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Figure A2.4 Heat map of V-gene usage for 53,679 VH:VL clusters recovered from Donor 2.  Sequences were collected using primers 
targeting the framework 1 region; raw data is available in the online supplement. 
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Figure A2.5 Heat map of V-gene usage for 15,372 VH:VL clusters recovered from Donor 3.  Sequences were collected using primers 
targeting the leader peptide region; raw data is available in the online supplement.
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Figure A2.6 VH alignment of the six VRC26 HIV broadly neutralizing antibody variants 
recovered by PacBio sequencing of complete ~850bp VH:VL amplicons.  
Sequences were recovered from CD27
+
 peripheral B cells of the CAP256
donor and aligned to the VRC26 VH unmutated common ancestor (UCA, 
Doria-Rose et al., Nature 2014).  Corresponding light chain variants are 
shown in Figure A2.7. 
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Figure A2.7 VL alignment of the six VRC26 HIV broadly neutralizing antibody variants 
recovered by PacBio sequencing of complete ~850bp VH:VL amplicons.  
Sequences were recovered from CD27
+
 peripheral B cells of the CAP256
donor and aligned to the VRC26 VL unmutated common ancestor (UCA, 
Doria-Rose et al., Nature 2014).  Corresponding heavy chain variants are 
shown in Figure A2.6. 
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Figure A2.8 Comparison of the number of non-templated bases (sum of somatic mutations and 
non-templated insertions) in the top 50 public, promiscuous VL nucleotide 
junctions shared by Donors 1, 2, and 3 to 50 randomly selected VL junctions paired 
with only a single heavy chain in the Donor 1, Donor 2, or Donor 3 repertoires 
(means.d.).  Statistical significance noted where p < 0.05 (* p < 10–10 compared to
all other groups, ** p = 0.0043). 
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Heavy Chain 
  
  
1H 2H 3H 4H 5H 6H 7H 8H 9H 10H 11H Total 
L
ig
h
t 
C
h
a
in
 
1L 1,842 4 20 13 18 16 39 20 49 6 4 2,031 
2L 0 4,916 34 31 59 41 102 127 146 28 8 5,492 
3L 0 2 6,251 9 38 25 116 60 118 13 2 6,634 
4L 21 27 75 14,592 81 158 348 189 397 75 51 16,014 
5L 5 15 97 41 16,204 99 192 231 277 86 19 17,266 
6L 2 12 92 37 64 16,427 358 180 404 62 23 17,661 
7L 9 13 218 72 112 180 21,315 203 1,320 78 45 23,565 
8L 4 39 85 71 242 145 365 32,393 506 79 72 34,001 
9L 4 29 182 105 116 186 1,335 323 35,391 109 46 37,826 
10L 12 24 944 189 1,597 1,080 3,519 1,898 4,291 8,535 98 22,187 
11L 32 66 1,153 272 1,258 1,655 6,405 6,567 6,185 555 14,126 38,274 
 
Total 1,931 5,147 9,151 15,432 19,789 20,012 34,094 42,191 49,084 9,626 14,494 220,951 
 
Table A2.1 VH:VL pairing analysis of a mixture of HEK293 cells transfected with 11 different known antibodies.  The maximum 
read count for each row and column is highlighted; 11/11 antibodies were identified and paired correctly in this control 
experiment.  Read count variation was expected due to varying transfection & expression efficiency for the 22 distinct 
heavy and light chain plasmids, and antibody clones #10 and 11 exhibited notable VH-VL imbalance by total read 
counts.  The signal:topVLnoise ratio (the relevant parameter for native pair assignment, see Table A2.2) averaged 35:1 
overall and 87:1 if noise from light chains 10 and 11 (which showed VH-VL imbalance, see total VH and VL reads) was 
excluded.    
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Estimated input human B cells 20,000 
Estimated ARH-77 spiked cells 260 
VH:VL Reads after CDR3 clustering 403,897 
Recovered CDR-H3:CDR-L3 Clusters 1,751 
Correct ARH-77 VH:VL Reads (Signal) 2,604 
ARH-77 Top Incorrect VL Reads (topVLnoise) 27 
ARH-77 2nd-Ranked Incorrect VL Reads 19 
ARH-77 3rd-Ranked Incorrect VL Reads 16 
ARH-77 Signal:topVLnoise Ratio
*
96.4 
* 
The key metric for VH:VL pair assignment (see main text) 
Table A2.2 Accuracy statistics for human VH:VL paired analysis with an ARH-77 immortalized 
cell line control spike.
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Sample 
FACS Count Hemocytometer Count 
Fresh Bmems After 4d Activation 
Donor 1 1.8 million 1.6 million viable 
Donor 2 1.1 million 1.3 million viable 
Donor 3 347k 300k viable 
ARH-77 spike 
experiment 
87k 20k viable 
Table A2.3 Memory B cell counts before and after in vitro activation.  Values must be 
considered rough estimates due to varying contributions of hemocytometer 
sampling, centrifugation/recovery cell loss, and cell death, stasis, and 
expansion over four days in vitro. 
125 
Conc (nM) Primer ID Primer Sequence 
40 VH1_LP tattcccatcgcggcgcACAGGTGCCCACTCCCAGGTGCAG 
40 VH3_LP tattcccatcgcggcgcAAGGTGTCCAGTGTGARGTGCAG 
40 VH4/6_LP tattcccatcgcggcgcCCCAGATGGGTCCTGTCCCAGGTGCAG 
40 VH5_LP tattcccatcgcggcgcCAAGGAGTCTGTTCCGAGGTGCAG 
40 hV1for_LP gcgccgcgatgggaataNNNNNNNNNNNNNNNNTCTGCTCGAGTTCGGTCAGGTCCTGGGCCCAGTCTGTGCTG 
40 hV2for_LP gcgccgcgatgggaataNNNNNNNNNNNNNNNNTCTGCTCGAGTTCGGTCAGGTCCTGGGCCCAGTCTGCCCTG 
40 hV3for-2_LP gcgccgcgatgggaataNNNNNNNNNNNNNNNNTCTGCTCGAGTTCGGTCAYWCTGCACAGGCTCTGTGACCTCCTAT 
40 hV4/5for_LP gcgccgcgatgggaataNNNNNNNNNNNNNNNNTCTGCTCGAGTTCGGTCAGGTCTCTCTCSCAGCYTGTGCTG 
40 hV6for_LP gcgccgcgatgggaataNNNNNNNNNNNNNNNNTCTGCTCGAGTTCGGTCAGTTCTTGGGCCAATTTTATGCTG 
40 hV7for_LP gcgccgcgatgggaataNNNNNNNNNNNNNNNNTCTGCTCGAGTTCGGTCAGGTCCAATTCYCAGGCTGTGGTG 
40 hV8for_LP gcgccgcgatgggaataNNNNNNNNNNNNNNNNTCTGCTCGAGTTCGGTCAGAGTGGATTCTCAGACTGTGGTG 
40 hV1/2for_LP gcgccgcgatgggaataNNNNNNNNNNNNNNNNTCTGCTCGAGTTCGGTCAATGAGGSTCCCYGCTCAGCTGCTGG 
40 hV3for_LP gcgccgcgatgggaataNNNNNNNNNNNNNNNNTCTGCTCGAGTTCGGTCACTCTTCCTCCTGCTACTCTGGCTCCCAG 
40 hV4for_LP gcgccgcgatgggaataNNNNNNNNNNNNNNNNTCTGCTCGAGTTCGGTCAATTTCTCTGTTGCTCTGGATCTCTG 
Table A2.4 Leader peptide overlap extension primers. 
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Figure A3.1 V-gene pairing surface plot for B-cell receptors observed in Donor 1, separated by heavy chain isotype. 
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Figure A3.2 V-gene pairing surface plot for B-cell receptors observed in Donor 2, separated by heavy chain isotype. 
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Figure A3.3 Fraction IgK light chain gene usage across B cell subsets for Donors 1, 2, and 3.  Error bars indicate standard 
deviation for averaged values. 
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Figure A3.4 CDR-H3:CDR-L3 length heat maps of (a) naïve donor repertories, and (b) antigen-experienced donor repertoires. 
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Figure A3.5 CDR-L3 loop charge in naïve and antigen-experienced antibody repertoires for Donor 1 (left) and Donor 2 
(right), subdivided by IgK (top) and IgL (bottom).  This figure demonstrates that kappa and lambda repertoires 
exhibit distinct CDR-L3 charge distributions (top compared to bottom graphs).  All naïve repertoires were 
statistically significant from antigen-experienced repertoires in the same group by the K-S test (D1-K, D2-K, D2-
L p < 10
-14
, D1-L p < 10
-10
); n for all distributions are provided in Table A3.2.
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Figure A3.6 Charge distributions for naïve and antigen-experienced repertoires of 
Donors 1 and 2, further subdivided by CDR-H3:CDR-L3 total charge (top), 
CDR-H3 charge (middle), and CDR-L3 charge (lower). 
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Figure A3.7 Relative representation ratio heat map of CDR-H3:CDR-L3 charge combinations across naïve and antigen-
experienced repertoires.  Values represent the ratio of antigen-experienced:naïve repertoire fractional 
representation for a given H3:L3 charge combination; red and blue shading represents relative increases and 
decreases in representation in antigen-experienced compared to naïve repertoires, respectively. 
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ID logFC AveExpr t P.Value adj.P.Val 
HV3-33:KV1-8 -4.625 2.934 -7.087 5.08E-06 2.68E-03 
HV6-1:KV1-33 -4.510 3.723 -6.968 6.14E-06 2.68E-03 
HV4-34:KV1-8 -4.127 3.796 -5.959 3.31E-05 8.46E-03 
HV3-74:KV4-1 3.986 3.933 5.789 4.47E-05 8.46E-03 
HV3-74:KV2-28 4.151 3.044 5.742 4.85E-05 8.46E-03 
HV6-1:LV3-19 -3.624 2.692 -5.238 1.20E-04 1.38E-02 
HV3-74:LV2-8 3.510 2.410 5.139 1.45E-04 1.38E-02 
HV1-69:KV1-8 -3.952 3.334 -5.098 1.56E-04 1.38E-02 
HV3-7:KV4-1 3.595 4.312 5.096 1.57E-04 1.38E-02 
HV3-15:KV2-28 3.455 3.317 5.043 1.73E-04 1.38E-02 
HV1-18:KV1-8 -3.454 3.035 -5.041 1.74E-04 1.38E-02 
HV3-74:LV1-51 3.289 2.490 4.857 2.45E-04 1.59E-02 
HV4-59:KV1-8 -3.292 4.021 -4.827 2.59E-04 1.59E-02 
HV6-1:LV1-40 -3.251 3.659 -4.813 2.67E-04 1.59E-02 
HV1-24:LV2-14 -3.250 4.539 -4.798 2.74E-04 1.59E-02 
HV1-58:KV1-33 -3.039 2.682 -4.530 4.58E-04 2.49E-02 
HV4-34:LV3-1 -2.907 4.976 -4.337 6.65E-04 3.14E-02 
HV5-51:KV1-8 -3.339 2.720 -4.307 7.04E-04 3.14E-02 
HV1-3:KV4-1 3.324 3.625 4.291 7.26E-04 3.14E-02 
HV1-58:LV3-1 -2.873 2.283 -4.258 7.75E-04 3.14E-02 
HV3-30:KV1-8 -2.917 3.613 -4.248 7.90E-04 3.14E-02 
HV6-1:LV3-1 -3.043 3.618 -4.236 8.09E-04 3.14E-02 
HV1-58:KV1-39 -3.768 3.078 -4.224 8.27E-04 3.14E-02 
HV4-61:KV3-20 2.963 3.795 4.061 1.14E-03 3.99E-02 
HV1-69:LV3-1 -2.638 5.963 -4.059 1.14E-03 3.99E-02 
HV3-21:KV1-8 -2.767 3.706 -3.985 1.32E-03 4.35E-02 
HV2-26:KV1-33 -2.606 3.537 -3.977 1.35E-03 4.35E-02 
HV1-46:KV1-33 -2.554 5.407 -3.910 1.54E-03 4.79E-02 
Table A3.1 Statistically significant differentially expressed heavy/light V-gene pairs with 
adjusted p < 0.05 between naïve and antigen-experienced antibody 
repertoires (abbreviations:  logFC log2 fold change between conditions, 
AveExpr log2 average expression across all observed values, t moderated t-
statistic, P.Value associated p-value, adj.P.val adjusted p-value.) 
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Isotype Cell subset Donor 1 Donor 2 
IgK 
Naïve 8,521 11,312 
Ag-Exp 19,755 49,844 
IgL 
Naïve 4,919 13,860 
Ag-Exp 14,067 36,126 
Table A3.2  Recovered IgK and IgL pairs for Donor 1 and Donor 2 among naïve and 
antigen-experienced subsets.  These data are represented graphically in 
Figure 4.6. 
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Donor CDR-H3_aa CDR-L3_aa CDR-H3_nt CDR-L3_nt Gene usage 
1 ARSSRGAAAGFDY GTWDSSLSA-VV gcgagaAGCTCGAGGGGagcagcagcCGGTtttgactac ggaacatgggacagcagcctgagtgct---gtggta 
HV4-59:D6-
13:J4/λV1-51:J2 
3 ARSSRGAAAGFDY GTWDSSLSAGVV gcgagaTCTTCCCGCGGagcagcagctggttttgactac ggaacatgggatagcagcctgagtgctggGgtggta 
HV4-59:D6-
13:J4/λV1-51:J2 
2 ARSSRGAAAGFDY (LQNAGVTGT) gcgagaTCTTCACGCGGGgcagcagctggttttgactac (ctgcagaatgctggcGTAACGGggacg) 
HV4-59:D6-
13:J4/κV3-20:J1 
2 ANEIRPNDY LISYTDARIWV gcgaacgaAATAAGACctaatgactac ttaatctcctatactgatgctcgAATttgggtg 
HV3-23:D3-
3:J4/λV7-46:J3 
3 ANEIRPNDY LLSYGDV--WV gcgaacgaGATCCGACCCAatgattat ttgctctcctacggtgatg------tttgggtg 
HV3-23:D1-
14:J4/λV7-46:J3 
1 ARARGYSYGYSDY QKYNSAPALT gcgagagCTCgtggatacagctatggttactctgactac caaaagtataacagtgccccCGCgctcact 
HV1-8:D5-
18:J4/κV1-27:J4 
3 ARARGYSYGYSDY QKYNSAPP-T gcgagagCCCgtggatacagctatggttactctgactac caaaagtataacagtgcccctcc---cact 
HV3-48:D5-
18:J4/κV1-27:J4 
1 ARGHYGLDV QQYGSSPIT gcgagagGACactacggtttggacgtc cagcaatatggtagctcaccgatcacc 
HV3-11:-
:J6/κV3-20:J5 
2 ARGHYGLDV QQYGSSSRT gcgagagGTCactacggtttggacgtc cagcagtatggtagctcatctcGAacg 
HV3-7:-:J6/κV3-
20:J1 
1 ARGEDYYYGMDV QSIDTDGTHGVV gccaggggggaAGactactactacggtatggacgtc cagtcaattgacaccgatggtactcatGGtgtggta 
HV3-11:D3-
16:J6/λV3-25:J2 
2 ARGEDYYYGMDV QSADSSGTY-VV gcgcgaggtgaAGactactactacggtatggacgtc caatcagcagacagcagtggcactta---tgtggta 
HV3-11:D2-
21:J6/λV3-25:J2 
Table A3.3 Selected nucleotide sequences for public ag-exp CDR-H3 amino acid BCR.  Donor 3 in this analysis corresponds 
to Donor 3 in a previous study
83
.  Non-templated bases are in bold/caps and deviations from germline underlined.
Distinct nucleotide sequences and CDR-L3 lengths indicated distinct heavy and light recombination events.
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